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Introduction
Cholera and dysentery have afflicted humankind for centuries. The 
epidemics they cause have affected the outcome o f wars and the fates of 
countries. In much o f the world, epidemic cholera and dysentery are uncom­
mon, but during the past decade these two diseases have re-emerged as causes 
of significant morbidity and mortality in many developing countries.
Only a few pathogens cause epidemic diarrhea, although there are many that 
cause sporadic diarrhea. In developing countries, two etiologic agents are 
responsible for most epidemic diarrhea: toxigenic Vibrio choJerae serogroup O1, 
which causes watery diarrhea, and ShigeJJa dysenteriae serotype 1, which 
causes bloody diarrhea. Recently, two additional organisms have emerged to 
cause epidemic diarrhea, Vibrio choJerae serogroup O139, which causes watery 
diarrhea, and Escherichia coJi serotype O157:H7, which causes bloody diarrhea. 
The latter is a common agent o f diarrhea only in developed countries.
This manual focuses on the epidemiology o f these four organisms and the 
laboratory methods used to identify them and to test their susceptibility to 
antimicrobial agents in the epidemic setting. The laboratory techniques and 
study methodology described provide accurate and useful information for the 
control o f epidemics using a minimum of resources. The manual emphasizes 
coordination of the activities of the microbiologist and the epidemiologist in 
order to obtain information that can be generalized to develop effective 
treatment policies for these epidemic diarrheal diseases. It encourages focused 
studies to determine the organisms causing epidemics and their antimicrobial 
susceptibility patterns rather than relying on random information that may not 
accurately represent a situation.
Often the countries that face the challenge o f responding to an epidemic are 
those with the least resources. Therefore, the microbiology laboratory must 
use its resources wisely in order to have the greatest impact on reducing 
morbidity and mortality during an epidemic. There may be several ways to 
reach the end result o f identifying the organism causing the outbreak or the 
epidemic. Often, however, a small added benefit requires a much larger 
expenditure o f materials and time. In this manual this problem is addressed 
specifically. The procedures described are not new; most have been used for a 
number of years. However, these procedures were specifically selected for 
testing specimens from outbreaks rather than for general use in a clinical 
microbiology laboratory. The selected procedures minimize the materials 
needed by the laboratory while deriving the most useful information.
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Chapter 1 
The Public Health Role of Clinical Laboratories
A. Epidemic Diarrhea
The two most common types o f epidemic diarrhea in developing countries 
are watery diarrhea caused by Vibrio cholerae serogroup O1 and bloody 
diarrhea caused by Shigella dysenteriae serotype 1 (Sd1). This chapter presents 
an overview o f these and other organisms that cause epidemic dysentery and 
cholera. Knowing the epidemiology and clinical presentation o f these organisms 
will aid in understanding the procedures presented in the following chapters.
1. Epidemic cholera
Cholera is a secretory diarrheal disease caused by enterotoxin-producing 
strains o f V. cholerae. Although over 150 serogroups o f V. cholerae have been 
identified, for decades toxigenic V. cholerae serogroup O1 was the only known 
cause of epidemic cholera. After a large epidemic in Asia in 1992 and 1993, it 
became clear that toxigenic V. cholerae serogroup O139 also could cause 
epidemics very similar to those caused by V. cholerae O1. According to World 
Health Organization (WHO) guidelines, both V. cholerae O1 and O139 are now 
recognized causes o f cholera and should be reported the same way. Isolates of 
non-O1 and non-O139 V. cholerae can cause illness, but they do not pose the 
public health threat o f the O1 and O139 serogroups.
Additional details on the epidemiology, historical background, clinical manifes­
tations and treatment o f cholera are presented in Chapter 5.
2. Epidemic dysentery
Dysentery, defined as diarrhea with visible blood, can be caused by many 
different organisms, including Shigella spp., enterohemorrhagic Escherichia coli 
serotype O157:H7, Cam pylobacter je jun i, enteroinvasive E. coli, Salm onella 
spp. and, infrequently, Entamoeba histolytica. Of these organisms, the only 
ones known to cause large epidemics are Shigella dysenteriae serotype 1 (Sd1), 
and much less frequently, E. coli O157:H7. Additional details on the epidemiol­
ogy, historical background, clinical manifestations and treatment o f Sd1 infec­
tion are presented in Chapter 3.
Although uncommon, a species o f parasitic ameba, E. histolytica, deserves 
mention. This organism is an occasional cause o f dysentery, especially in young 
adults, but does not cause epidemic disease. Asymptomatic infection with 
E. histolytica , however, is frequent in developing countries, being present in up 
to 10% of healthy persons. Examination o f specimens should be done by a 
trained microscopist since the organism must be differentiated from nonpatho- 
genic amebae and from white blood cells, which are often mistaken for amebic
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trophozoites. In some epidemics o f dysentery due to Sd1, E. histolytica  was also 
identified and initially thought to be the cause. Because o f this incorrect 
diagnosis, persons with dysentery were treated with anti-amebic drugs, resulting 
in continued transmission of Sd1 and excess preventable mortality. Finding 
E. histolytica  in a bloody stool during an epidemic o f dysentery does not 
indicate that it is the cause o f the epidemic, or even that it is the cause of  
dysentery in an individual patient.
E. coli O157:H7 has caused at least one large outbreak o f dysentery in 
southern Africa. It is suspected to have caused additional outbreaks, but these 
were not confirmed by microbiologic culture. E. coli O157:H7 is included in 
this manual so that laboratory workers will be familiar with the organism and 
will be able to identify it if  necessary. It may return in the future to cause 
additional epidemics; laboratories must be prepared to identify it.
Additional details on the epidemiology, historical background, clinical 
manifestations and treatment o f E. coli O157:H7 are presented in Chapter 7.
B. Public Health Role of the Laboratory
Clinical laboratories play an especially crucial public health role during 
epidemics. A laboratory may be the only one in a country that can quickly 
provide the information needed to develop appropriate treatment policy during 
an epidemic. In countries with scarce resources, the role o f the laboratory is 
to use those resources to provide the best information for developing treatment 
policy, rather than to focus on the diagnosis o f individual patients. During an 
epidemic of cholera or dysentery, the laboratory has four primary roles:
• Initial identification o f the organism causing the epidemic
• Initial determination of the antimicrobial susceptibility patterns
• Monitoring for changes in antimicrobial susceptibility patterns
• Defining the duration and geographic extent o f the epidemic
The World Health Organization (WHO) recommends that countries at risk for 
epidemics establish an epidemic control committee. Since the laboratory plays 
an important role in the identification and control o f epidemics, a microbiologist 
should be a part o f the epidemic control committee.
1. Initial identification of the organism causing the epidemic
Preparation/laboratory network
In countries at risk for epidemics o f dysentery or cholera, the laboratory’s 
first role is to be prepared for an epidemic. This means having the supplies (or 
ready access to supplies) necessary to identify V. cholerae O1/O139 and 
Shigella. Annexes A and B in this manual list laboratory supplies required for 
isolation, identification, and antimicrobial susceptibility testing. A country-wide 
public health laboratory network should be established (see Annex C). All 
countries should have at least one national or central laboratory capable of
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identifying V. cholerae O1/O139 and Shigella, determining antimicrobial suscep­
tibility, and sending isolates to an international reference laboratory (Annex D).
To maintain a laboratory’s capability to determine the antimicrobial suscepti­
bility patterns o f bacterial pathogens accurately and reproducibly, investments 
must be made in the infrastructure o f the laboratory. These investments include a 
steady supply o f the material resources needed to perform appropriate testing; a 
trained staff with expertise to conduct the laboratory tests and sufficient time, 
materials, and supplies to maintain this expertise; and quality control o f the staff, 
supplies, and reagents. Because antimicrobial susceptibility testing is so resource 
intensive, WHO recommends that this testing be carried out at only one or two 
laboratories in the country. Peripheral laboratories may perform initial isolation 
o f Vibrio spp. or Shigella spp., and then refer isolates to the central or national 
reference laboratory for final confirmation and determination o f antimicrobial 
susceptibility. Peripheral laboratories may also be the sites o f focused studies to 
determine etiologic agents causing an outbreak. First-level laboratories should be 
supplied with transport medium and the means o f sending the specimens to 
the next level laboratory or to the central laboratory.
Diagnosing epidemics
During a suspected epidemic, the laboratory will determine the organism 
causing the epidemic and its antimicrobial susceptibilities. An epidemic may be 
suspected on clinical grounds: for instance, a surveillance system based on 
clinical diagnosis may note an increase in the number o f cases o f diarrhea. The 
laboratory should become involved as soon as possible to identify the causative 
agent. This underscores the need for good communication between the labora­
tory, the epidemiologists, and clinicians and other health care workers.
At times, the laboratory may be the first to suspect an epidemic. Laboratory 
workers may note an increase in the number o f stool specimens submitted, an 
increase in the proportion o f stool specimens with blood, or the appearance o f a 
new organism. When a laboratory worker suspects an outbreak or epidemic, he 
or she should contact the appropriate clinicians and public health authorities as 
soon as possible.
Once the organism causing the epidemic is identified, it is not necessary to 
examine a large number o f stool specimens. Patients can be treated on the basis 
o f their syndrome.
D iagnosing dysentery epidem ics
If an epidemic o f dysentery is suspected, the most common cause in most parts 
o f the world is Sd1. During an outbreak or epidemic, Sd1 is likely to be isolated 
much more frequently than the other organisms that cause dysentery. Therefore, a 
laboratory should conserve its resources and, according to WHO guidelines, once 
Sd1 has been confirmed as the cause o f an epidemic, patients presenting with 
dysentery should initially be treated as if  they are infected with Sd1. There is no
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need for the laboratory to examine the stools o f all patients. Rather, it is better 
to take specimens from a small number o f patients during an outbreak or to 
conduct periodic surveillance for organisms causing dysentery (see below).
If Sd1 is not isolated during a suspected outbreak, the laboratory should test 
for E. coli O157:H7. If neither o f these organisms is isolated, arrangements 
should be made to send specimens to a reference laboratory.
Besides Sd1 and E. coli O157:H7, a number o f organisms contribute in 
various proportions to the burden o f dysentery in a country. The predominant 
causes o f dysentery will vary by geographic location and time o f year. Seasonal 
peaks occur and may reflect changes in the proportions o f the various causative 
organisms. Laboratories should conduct periodic surveys o f the organisms 
causing dysentery in order to monitor antimicrobial susceptibility patterns and to 
help clinicians and public health authorities develop rational guidelines for 
empiric treatment. Procedures for conducting such surveys are described in 
Annex E.
D iagnosing cholera epidem ics
If an epidemic o f cholera is suspected, the most common cause is 
V cholerae O1. If V cholerae O1 is not isolated, the laboratory should test 
for V. cholerae O139. If neither o f these organisms is isolated, arrangements 
should be made to send stool specimens to a reference laboratory.
Infection with V. cholerae O139 should be handled and reported in the same 
manner as that caused by V. cholerae O1. The associated diarrheal illness 
should be called cholera and should be reported as a case o f cholera to the 
appropriate public health authorities.
2. Determining antimicrobial susceptibility patterns of epidemic 
organisms
Antimicrobial susceptibilities should be determined for the first 30 to 50 
isolates identified by the laboratory at the beginning o f an epidemic. That 
number will provide sufficient information to develop antimicrobial treatment 
policy for the organism. After that, the laboratory should conduct periodic 
surveys to detect any changes in antimicrobial susceptibility patterns (see Annex E).
The laboratory should not routinely test antimicrobial agents that are not 
available in the country or antimicrobial agents that are not recommended by 
WHO as efficacious in the treatment o f cholera or dysentery (see Chapters 3 
and 5). In addition, if  all isolates are resistant to a particular antimicrobial agent 
during the first round o f testing (for example, Sd1 resistance to ampicillin or 
trimethoprim-sulfamethoxazole), it is probably not useful to test against those 
agents during future surveys.
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Once the organisms are isolated and the antimicrobial susceptibility patterns 
determined, these results should be transmitted as quickly as possible to the 
national epidemiologist and to other public health officials. They can then be 
used to make rational choices for antimicrobial treatment policy.
It is useful to send 10 to 20 o f the initial isolates to an international reference 
laboratory for confirmation o f the identification and antimicrobial susceptibility 
pattern (Annex D).
3. Monitoring for changes in antimicrobial susceptibility
As the epidemic progresses, periodic surveys of 30 to 50 isolates o f the epi­
demic organism should be carried out to detect any changes in the antimicrobial 
susceptibility pattern o f the organism causing the epidemic. These should be 
conducted every 2 to 6 months, depending on conditions and resources. Any 
changes should be reported to the national epidemiologist and to other public 
health officials to modify the antimicrobial treatment policy. If any major changes 
are noted, it is useful to send isolates to an international reference laboratory for 
confirmation (Annex D).
4. Defining the duration of the epidemic
The laboratory can help define the end o f the epidemic, especially with cholera 
epidemics. In the course o f an epidemic, the number o f cases may decrease for 
several reasons: seasonal variation, transition to an endemic state, or disappear­
ance o f cholera from an area. Cholera may nearly disappear in cool seasons, only 
to reappear in the summer months. The laboratory can assist in determining if  the 
epidemic has actually ended by periodically analyzing stool specimens from 
patients with acute watery diarrhea. In order for an area to be declared cholera­
free by WHO, twice the incubation period (a total o f 10 days) must pass without 
evidence o f V. cholerae O1/O139. However, because of seasonal variation, 
surveillance should be maintained for at least 12 months.
Similarly, seasonal variation is seen with epidemic dysentery. The laboratory 
can periodically analyze stool specimens from patients with dysentery to see if  
Sd1 is still present in a particular area.
5. Other duties of the laboratory during an epidemic
In addition to the major duties outlined above, the laboratory can support other 
activities related to the epidemic.
Epidemiologic studies
At times, the laboratory may be asked to provide laboratory support to an 
epidemiologic study. By combining epidemiologic and laboratory data, studies 
that examine modes o f transmission or risk factors for illness can be more 
specific and provide better information for the control o f the epidemic.
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Defining the magnitude of the epidemic and improving 
surveillance data
Cultures taken from a series o f patients that meet the clinical case definition 
used during an epidemic can determine the predictive value o f the definition. Such 
studies will confirm the accuracy o f the case definition used for surveillance 
purposes and can provide a more accurate picture o f the magnitude o f the 
epidemic.
In addition, the laboratory may be called upon to support other activities such 
as environmental monitoring for V. cholerae O1/O139. These requests place 
additional demands on the resources o f the laboratory. Therefore, the microbiolo­
gist must be part o f the decision-making process to determine whether the 
laboratory has the capacity to support the particular request and whether it is 
an appropriate use o f the laboratory resources.
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Collection and Transport of Fecal Specimens
Fecal specimens should be collected in the early stages o f any enteric illness, 
when pathogens are usually present in the stool in highest numbers, and before 
antibiotic therapy has been started (Table 2-1).
T ab le  2-1. Collection an d  t ranspor t  of s p e c im en s  for laboratory d iagnosis
When to collect




When the patient is having diarrhea, as soon after 
onset o f illness as possible (preferably within 4 days of 
onset) and before antimicrobial treatment is started.
Rectal swab or swab o f fresh stool in transport 
medium.
Cary-Blair or other suitable transport medium (NOT 
buffered glycerol saline for V. cholerae).
Refrigerate at 4°C if  the specimens will be received by 
the laboratory within 48 hours, or freeze at -70°C. 
Fecal specimens from patients with suspected cholera 
can be transported at ambient temperature and held for 
longer times if  necessary; however, refrigeration is 
preferred.
Seal tubes/containers to prevent leakage; place in 
waterproof container to protect from wet or dry ice. 
Ship in insulated box with ice packs, wet ice, or dry ice 
by overnight delivery.
Stool specimens or rectal swabs should be collected from 10-20 persons who 
meet the following criteria:
• Currently have watery diarrhea (cholera) or bloody diarrhea (dysentery)
• Had onset o f illness less than 4 days before sampling
• Have not received antimicrobial treatment for the diarrheal illness
A. Collection of Stool
Collect stools from patients in clean containers without disinfectant or 
detergent residue and with tight-fitting, leak-proof lids. Specimens should not 
be collected from bedpans, as they may contain residual disinfectant or other 
contaminants. Unpreserved stool should be refrigerated if  possible and 
processed within a maximum of 2 hours after collection. Specimens that 
cannot be cultured within 2 hours of collection should be placed in transport 
medium and refrigerated immediately.
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1. Placing stool in transport medium
A small amount o f stool can be collected by inserting a sterile cotton- or 
polyester-tipped swab into the stool and rotating it. If mucus and shreds of 
intestinal epithelium are present, these should be sampled with the swab. Immedi­
ately insert the swab into transport medium. (The transport medium should have 
been chilled for 1 to 2 hours, if  possible.) The swab should be pushed completely 
to the bottom o f the tube o f transport medium and the top portion o f the stick 
touching the fingers should be broken off and discarded. Replace the screw cap 
and tighten firmly. Place the tube in a refrigerator or cold box.
2. Collection of rectal swabs
Rectal swabs may be collected as follows: moisten the swab in sterile transport 
medium, insert through the rectal sphincter 2 to 3 cm (1 to 1.5 inches) and rotate, 
withdraw and examine to make sure there is some fecal material visible on the 
swab. Immediately insert the swab into cold transport medium as described in 
above paragraph. Place the tube in a refrigerator or cold box.
The number o f swabs needed will depend on the number o f plates to be inocu­
lated. In general, if  specimens will be examined for more than one pathogen, at 
least two stool swabs or rectal swabs should be collected per patient, and both 
swabs should be inserted into the same tube o f transport medium.
F ig u re  2-1. Cary-Blair semisolid t ransport  medium
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3. Transport media 
Cary-Blair transport medium
Cary-Blair transport medium can be used to transport many enteric pathogens, 
including Shigella, Vibrio cholerae, and Escherichia coli O157:H7 (Figure 2-1). 
Cary-Blair’s semisolid consistency provides for ease of transport, and the 
prepared medium can be stored after preparation at room temperature for up to 1 
year. Because o f its high pH (8.4), it is the medium of choice for transport and 
preservation o f V cholerae.
Preparation and  qua lity  contro l o f  C ary-B lair
Prepare according to manufacturer’s instructions. [Note: There are several 
commercially available dehydrated formulations o f Cary-Blair. Some require the 
addition o f calcium chloride and some do not. Cary-Blair can also be prepared 
from individual ingredients.] When Cary-Blair is prepared, it should be dispensed 
into containers in sufficient volume so that swabs will be covered by at least 4 cm 
o f medium. For example, 5- to 6-ml amounts may be dispensed into 13 x 100­
mm screw cap tubes. With the caps loosened, sterilize by steaming (do not 
autoclave) at 100°C for 15 minutes. Tighten the caps after sterilization.
Cary-Blair is quite stable if  stored in tightly sealed containers in a cool dark place 
so that the medium does not dry out. Cary-Blair may be used for up to 1 year as 
long as there is no loss of volume, contamination, or color change.
Other transport media
Other transport media that are similar to Cary-Blair are Amies’ and Stuart’s 
transport media. Both o f these are acceptable for Shigella  and E. coli O157:H7, 
but they are inferior to Cary-Blair for transport o f V. cholerae.
Alkaline peptone water (APW) may be used to transport V. cholerae, but this 
medium is inferior to Cary-Blair and should be used only when the latter medium 
is not available. APW should not be used if  subculture will be delayed more than 
6 hours from the time o f collection because other organisms will overgrow vibrios 
after 6 hours.
Buffered glycerol saline (BGS), a transport medium that is used for Shigella, is 
unsuitable for transport of V. cholerae. Additional disadvantages o f BGS are that 
it can be used for only 1 month after it is made and, being a liquid medium, is 
more likely to leak or spill during transport.
4. Storage of specimens in transport medium
If transport medium has been stored at room temperature, it should be chilled, if  
possible, for 1 to 2 hours before use. Specimens preserved in transport medium 
should be refrigerated until processed. If specimens will be kept more than 2 to 3 
days before being cultured, it is preferable to freeze them immediately at -70°C.
It may be possible to recover pathogens from refrigerated specimens up to 7 days 
after collection; however, the yield decreases after the first 1 or 2 days. Prompt
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plating, refrigeration, or freezing o f specimens in Cary-Blair is particularly 
important for isolation o f Shigella, which is more fragile than other enteric 
organisms. Fecal specimens in transport medium collected from patients with 
cholera need not be refrigerated unless they are likely to be exposed to elevated 
temperatures (>40°C).
5. Unpreserved specimens
When transport medium is not available, one option for suspect V. cholerae 
specimens is to soak a piece o f filter paper, gauze, or cotton in liquid stool and 
place it into a plastic bag. The bag must be tightly sealed so that the specimen 
will remain moist and not dry out. Adding several drops o f sterile saline to the 
bag may help prevent drying o f the specimen. Refrigeration during transport is 
desirable but not necessary. This method is not suitable for transport o f Shigella 
or E. coli O157:H7 specimens and is less effective than transport medium for 
preserving V. cholerae organisms.
B. Preparing Specimens for Shipment
Specimen tubes should be clearly labeled with the specimen number, and if  
possible, the patient’s name and date o f collection. Write the numbers on the 
frosted portion o f the specimen tube, using an indelible marker pen. If there is no 
frosted area, write the information on a piece o f first-aid tape and fix this firmly 
on the specimen container. Patient information should be recorded on a data 
sheet; one copy should be sent with the specimens and another kept by the sender. 
A sample data sheet is provided in Annex F.
If a package is to be shipped by air, refer to packaging regulations presented in 
the publication, D angerous Goods Regulations (DGR). International A ir 
Transport Association (IATA). These regulations are summarized in Chapter 13, 
“Packing and Shipping o f Clinical Specimens and Etiologic Agents.” Even if  the 
package will be shipped by other means, these regulations are excellent guidelines 
for packing all infectious or potentially infectious materials.
1. Refrigerated specimens
Refrigerated specimens should be transported to the laboratory in an insulated 
box with frozen refrigerant packs or ice. If wet ice is used, place the tubes or 
containers in waterproof containers such as plastic bags that can be tightly sealed 
to protect the specimens from the water formed by melting ice.
2. Frozen specimens
Frozen specimens should be transported on dry ice. The following precautions 
should be observed:
• Place tubes in containers or wrap them in paper to protect them from dry ice.
Direct contact with dry ice can crack glass tubes.
• If the specimens are not in leakproof containers, protect them from exposure
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to carbon dioxide by sealing the screwcaps with tape or plastic film or by 
sealing the tubes in a plastic bag. Carbon dioxide will lower the pH o f the 
transport medium and adversely affect the survival o f organisms in 
the specimen.
• Ensure that the cool box is at least one-third full o f dry ice. If the specimens 
are sent by air and more than 2 kg o f dry ice is used, special arrangements 
may be necessary with the airlines. Airlines accept packages with less than 
2 kg o f dry ice.
• Address the package clearly, including the name and telephone number o f the 
receiving laboratory. Write in large letters: EMERGENCY MEDICAL 
SPECIMENS; CALL ADDRESSEE ON ARRIVAL; HOLD REFRIGER­
ATED (or “FROZEN” if  applicable). Be sure that all applicable labels and 
forms, such as those required by IATA, are correctly fixed to the outside of  
the package.
References
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Chapter 3 
Epidemiology of Dysentery Caused by Shigella
Epidemic dysentery in developing countries is usually caused by Shigella 
dysenteriae serotype 1 (Sd1). Sd1 is an unusually virulent enteric pathogen that 
causes endemic or epidemic dysentery with high death rates. It is the most 
common cause o f large-scale, regional outbreaks o f dysentery. In recent years,
Sd1 has caused epidemic dysentery in Central America, south Asia and central 
and southern Africa. An epidemic in Central America from 1969 to 1973 was 
responsible for more than 500,000 cases and 20,000 deaths. The epidemic in 
central and southern Africa began in 1979, initially affecting eastern Zaire, 
Rwanda and Burundi. In the early 1990s, epidemic dysentery moved southward, 
affecting first Zambia, then Malawi, Mozambique, Zimbabwe and southern 
Africa. A large rise in the number o f cases associated with refugee camps was 
seen in central Africa in 1994.
A. Epidemiology of Shigella
The genus Shigella is divided into four species: S. dysenteriae, S. flexneri, S. 
boydii, and S. sonnei. Each o f these species, with the exception of S. sonnei, has 
several serotypes (Table 3-1). In general, S. sonnei is more common in developed 
countries and S. flexneri and S. dysenteriae are more frequent in developing 
countries. The proportions o f each species vary from country to country. Sd1 
differs from the other Shigella species in several ways:
• Only Sd1 causes large and prolonged epidemics o f dysentery.
• Antimicrobial resistance develops more quickly and occurs more frequently in 
Sd1 than in other Shigella  species.
• Infection with Sd1 causes more severe, more prolonged, and more frequently 
fatal illness than does infection with other Shigella species.
T ab le  3-1. S p e c ies  an d  se ro g rou p s  of Shigella
Species Serogroup designation Serotypes
S. dysenteriae Serogroup A 1-13a,b
S. flexneri Serogroup B 1-6
S. boydii Serogroup C 1-18b
S. sonnei Serogroup D 1
a S. dysenteriae 1 has special significance since it is unusually virulent and causes endemic or 
epidemic dysentery with high death rates. Monovalent antiserum (absorbed) is required to identify
S. dysenteriae 1.
b Additional provisional serotypes have been reported but antisera to these new serotypes were not 
commercially available at the time this manual was printed.
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B. Clinical Manifestations
The hallmark o f infection with Sd1 is diarrhea with blood (dysentery). 
Shigella causes dysentery by invading and destroying cells that line the large 
intestine, leading to mucosal ulceration, a hemorrhagic inflammatory exudate 
and bloody diarrhea. Apart from bloody stools, patients with dysentery often 
have fever, abdominal cramps and rectal pain. However, the clinical response to 
infection spans a wide range, from mild to severe diarrhea with or without 
blood. In almost half o f cases, Shigella  causes acute nonbloody diarrheas that 
cannot be distinguished clinically from diarrhea caused by other enteric patho­
gens. Severity o f symptoms appears to be dose related. Asymptomatic infec­
tions may occur, but not to the extent that they do in Vibrio cholerae O1 
infections. A chronic carrier state does not occur, although the organisms may 
be excreted for several weeks. Sd1 infections are most often severe or fatal in 
young children and in the elderly and malnourished. Although most patients 
recover without complications within 7 days, persistent diarrhea may occasion­
ally occur.
Infection with Sd1 can be complicated by seizures, sepsis, rectal prolapse, or 
toxic megacolon. A more frequent complication is the hemolytic-uremic 
syndrome (HUS), which is characterized by the classic triad o f hemolytic 
anemia, thrombocytopenia and renal failure. HUS may be mild with rapid 
recovery, or severe, leading to kidney failure and death.
C. Treatment
The mainstay o f treatment for Sd1 infection is appropriate antimicrobial 
therapy, which lessens the risk o f serious complications and death. Other 
supportive measures should be used as well.
The following antimicrobial agents are currently recommended by WHO for 








The selection o f antimicrobial treatment should be based on recent susceptibil­
ity testing o f Sd1 strains from the area or from nearby areas if  Sd1 is new to 
the area (see Annex E). For developing a treatment policy, the antimicrobial 
agent chosen should be effective against at least 80% of local Sd1 strains, be 
given by mouth, be affordable, and be available locally or able to be obtained 
quickly. Unfortunately, resistance o f Sd1 to ampicillin and trimethoprim­
sulfamethoxazole has become widespread. Nalidixic acid, formerly used as a 
“backup” drug to treat resistant shigellosis, is now the drug o f choice in most
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areas, but resistance to it has appeared in many places. Pivmecillinam 
(amdinocillin pivoxil) is still effective for most strains o f Sd1 but may not be 
readily available. Fluoroquinolones (i.e., ciprofloxacin, norfloxacin, enoxacin) 
should be considered only if  Sd1 isolates are resistant to nalidixic acid. 
Fluoroquinolones are often costly and may not be readily available.
Currently, Sd1 strains are often resistant to ampicillin, trimethoprim­
sulfamethoxazole, metronidazole, streptomycin, tetracycline, chloramphenicol, 
and sulfonamides. In addition, although Sd1 may be susceptible to some 
antimicrobial agents in vitro, the drug may have no documented efficacy in vivo. 
Examples o f such agents are nitrofurans (e.g., nitrofurantoin, furazolidone), 
aminoglycosides (e.g., gentamicin, kanamycin), first- and second-generation 
cephalosporins (e.g., cephalexin, cefamandol), and amoxicillin.
Reference
World Health Organization. Guidelines for the control o f epidemics due to 
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Chapter 4 
Isolation and Identification of Shigella
Isolation and identification o f Shigella can be greatly enhanced when optimal 
laboratory media and techniques are employed. The methods presented here are 
intended to be economical and to offer laboratorians some flexibility in choice of  
protocol and media. Laboratories that do not have sufficient resources to adopt 
the methods described in this chapter should consider sending specimens or 
isolates to other laboratory facilities that routinely perform these procedures.
A. Isolation Methods
Figure 4-1 outlines the procedure for isolation o f Shigella from fecal 
specimens. Refer to Annex B for a list o f supplies necessary for laboratory 
identification o f Shigella .
For optimal isolation o f Shigella, two different selective media should be used: 
a general purpose plating medium of low selectivity, such as MacConkey agar 
(MAC), and a more selective agar medium, such as xylose lysine desoxycholate 
(XLD) agar. Desoxycholate citrate agar (DCA) and Hektoen enteric (HE) agar 
are suitable alternatives to XLD agar as media o f moderate to high selectivity.
Do not use SS agar as it frequently inhibits the growth of S. dysenteriae 
serotype 1.
When selective or differential media are incorrectly prepared, the reactions of 
organisms on those media can be affected. Therefore, it would be helpful to refer 
to Section D, “Media for isolation and identification o f Shigella ,” for a discussion 
o f these media, their preparation, and appropriate quality control strains.
There is no enrichment medium for Shigella that consistently provides a 
greater recovery rate than use o f direct plating alone.
1. Inoculation of selective agar
Fecal specimens should be plated as soon as possible after arrival in the 
laboratory. Selective media may be inoculated with a single drop o f liquid stool 
or fecal suspension. Alternatively, a rectal swab or a fecal swab may be used.
If a swab is used to inoculate selective media, an area approximately 2.5 cm 
(1 inch) in diameter is seeded on the agar plates, after which the plates are 
streaked for isolation (Figure 4-2). Media o f high selectivity such as XLD 
require more overlapping when streaking than media o f low selectivity. When 
inoculating specimens to a plate for isolation, it is important to use the entire plate 
to increase the chances o f obtaining well-isolated colonies. Incubate the plates 
for 18 to 24 hours at 35° to 37°C.
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S pecim en
1
M A C  and X L D









Antim icrobial susceptibility test
*K  = alkaline (red); A  = acid (yellow); - =  no H S  produced
F ig u re  4-1. P roce d u re  for recovery of Shigella from fecal s p ec im en s
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2. Isolation of suspected Shigella
After incubation, record the amount and type o f growth (e.g., lactose-ferment­
ing or lactose-nonfermenting) on each isolation medium for each patient specimen 
(a sample worksheet is presented in Figure 4-3). Colonies o f Shigella on MAC 
appear as convex, colorless colonies about 2 to 3 mm in diameter.
S. dysenteriae 1 colonies may be smaller (Table 4-1). Shigella colonies on XLD 
agar are transparent pink or red smooth colonies 1 to 2 mm in diameter.
S. dysenteriae 1 colonies on XLD agar are frequently very tiny, unlike other 
Shigella  species. Figures 4-4 to 4-7 show the typical appearance o f Shigella  on 
XLD and MAC. Select suspect colonies from the MAC and XLD plates and 
inoculate to appropriate screening media such as Kligler iron agar (KIA) or triple 
sugar iron agar (TSI).
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T able  4-1. A p p e a ra n c e  of Shigella co lonies on selective plating m edia
Isolation and Identification o f  Shigella
Selective agar medium Color of colonies Size o f colonies
M AC Colorless 2-3 mma,b
X L D  Red or colorless 1-2 mma,c
D CA Colorless 2-3 mma
H E Green 2-3 mma
a S. dysenteriae 1 colonies may be smaller.
b See Section D for discussion of different formulations of commercial dehydrated MacConkey agar 
and how selectivity is affected for isolation of Shigella. 
c S. dysenteriae 1 colonies on XLD agar are frequently very tiny, unlike other Shigella species.
B. Biochemical Screening Tests
Identification o f Shigella  spp. involves both biochemical and serologic testing. 
The use o f biochemical screening media is usually advisable to avoid wasting 
antisera. Most laboratories will find KIA (or TSI) to be the single most helpful 
medium for screening suspected Shigella isolates. If an additional test is desired, 
motility medium can be used to screen isolates before doing serologic testing. 
Section D in this chapter further describes these media.
1. Kligler iron agar and triple sugar iron agar
To obtain true reactions in KIA or TSI or other biochemical tests, it is neces­
sary to inoculate with a pure culture. Carefully select at least one of each type of 
well-isolated colony on each plate. Using an inoculating needle, lightly touch 
only the very center o f the colony. Do not take the whole colony or go through the 
colony and touch the surface o f the plate. This is to avoid picking up contami­
nants that may be on the surface o f the agar. If there is doubt that a particular 
colony is sufficiently isolated from surrounding colonies, purify the suspicious 
colony by streaking on another agar plate, after which the KIA or TSI slant may 
be inoculated.
KIA and TSI are inoculated by stabbing the butt and streaking the surface of  
the slant. After incubation for 18 to 24 hours at 35° to 37°C, the slants are 
observed for reactions typical o f Shigella. When incubating most biochemicals, 
caps should be loosened before placement in the incubator. This is particularly 
important for KIA and TSI. If the caps are too tight and anaerobic conditions 
exist, the characteristic reactions o f Shigella spp. may not occur and a misleading 
result could be exhibited. It is also important that KIA and TSI be prepared so 
that the tubes have a deep butt and a long slant (see Section D).
Shigella characteristically produces an alkaline (red) slant and an acid (yellow) 
butt, little or no gas, and no H2S (Table 4-2; Figure 4-8). A few strains o f S. 
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F ig u re  4-5. S. flexneri colonies on XLD
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F ig u re  4-6. S. flexneri and E  coli colonies on XLD. S. flexneri co lonies a re  colorless 
to red while the  E. coli co lonies a re  yellow.
F ig u re  4-7. S. flexneri colonies a p p e a r  colorless  on MAC. E. coli colonies are  
pink to red.
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Table 4-2. Reactions of Shigella in screening biochemicals
Screening medium Shigella reaction
KIA K/A, no gas produced (red slant/yellow butt)a
TSI K/A, no gas produced (red slant/yellow butt)a
H2S (on KIA or TSI) Negative
Motility Negative
Urea Negative
Indole Positive or negative
LIA K/A (purple slant/yellow butt)b
a K = alkaline (red); A = acid (yellow); some strains of S. fexneriserotype  6 and S. boydiiproduce  
gas from glucose.
b K = alkaline (purple); A = acid (yellow); an alkaline reaction (purple) in the butt of the medium 
indicates that lysine was decarboxylated. An acid reaction (yellow) in the butt of the medium 
indicates that lysine was not decarboxylated.
Figure 4-8. Reaction typical of 
Shigella in KIA (alkaline slant 
and acid butt)
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Motility agar should be inoculated with a straight inoculating needle, making a 
single stab about 1 to 2 cm down into the medium. Motility agar may be inocu­
lated with growth from a KIA or TSI that shows a reaction typical of Shigella. 
Alternately, motility agar can be inoculated at the same time as the KIA or TSI 
slant by using the same inoculating needle without touching the colony again. The 
motility agar should be inoculated first, after which, the KIA or TSI is inoculated 
by stabbing the butt first and then streaking the surface of the slant. Do not select 
a second colony to inoculate the KIA or TSI after the motility agar has been 
inoculated since it may represent a different organism.
Examine after overnight incubation at 35° to 37°C. Motility is indicated by the 
presence o f diffuse growth (appearing as clouding o f the medium) away from the 
line of inoculation (Figure 4-9). Nonmotile organisms do not grow out from the 
line o f inoculation. Motility reactions may be difficult for inexperienced 
laboratorians to read; therefore reactions should be compared with positive and 
negative control strains. Shigella  spp. are always nonmotile (Table 4-2).
The surface o f the motility agar should be dry when used. Moisture can cause a 
nonmotile organism to grow down the sides o f the agar creating a haze o f growth 
and appearing to be motile (see Section D).
Sulfide-indole-motility medium is a combination medium that is commercially 
available in dehydrated form (see Section D). It can be used in place o f motility 
medium.
2. Motility agar
F ig u re  4-9. Motility 
m edium  showing a 
nonmotile o rgan ism  in the 
left tube  and a  motile 
o rgan ism  in the  right tu b e
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3. Additional biochemical screening tests
Other biochemical tests such as urea medium and lysine iron agar may be used 
for additional screening o f isolates before testing with antisera. The value of  
these should be assessed before using them routinely (Table 4-2, Annex G).
These media, their preparation, and suggested quality control strains are described 
in Section D.
Urea m edium
Urea medium screens out urease-producing organisms such as K lebsiella  and 
Proteus. Urea agar is inoculated heavily over the entire surface o f the slant. 
Loosen caps before incubating overnight at 35° to 37°C. Urease positive cultures 
produce an alkaline reaction in the medium, evidenced by a pinkish-red color 
(Figure 4-10). Urease negative organisms do not change the color of the medium, 
which is a pale yellowish-pink. Shigella spp. are always urease negative (Table 4-2).
L ysine iron  agar
Lysine iron agar (LIA) is helpful for screening out Hafnia spp. and certain
E. coli, Proteus, and Providencia strains. LIA should be inoculated by stabbing 
the butt and streaking the slant. After incubation for 18 to 24 hours at 35° to 
37°C, organisms that produce lysine decarboxylase in LIA cause an alkaline 
reaction (purple color) in the butt of the medium and also on the slant (Figure 4-11). 
H2S production is indicated by a blackening of the medium. Organisms lacking 
lysine decarboxylase, produce an alkaline slant (purple) and an acid butt 
(yellow), no gas, and no H2S. Proteus and Providencia spp. will often produce a 
red slant caused by deamination o f the lysine. LIA must be prepared so that the 
tubes have a deep butt (see Section D).
Shigella  spp. are lysine negative and characteristically produce an alkaline 
(purple) slant and an acid (yellow) butt, no gas, and no H2S (Table 4-2).
C. Serologic Identification of Shigella
Serologic testing is needed for the identification o f Shigella  isolates. The genus 
Shigella  is divided into four serogroups, each group consisting o f a species that 
contains distinctive type antigens. The serogroups A, B, C, and D correspond to 
S. dysenteriae, S. flexneri, S. boydii, and S. sonnei, respectively. Three of the 
four, S. dysenteriae, S. flexneri, and S. boydii, are made up o f a number o f  
serotypes (see Chapter 3, Table 3-1).
Serologic identification is performed typically by slide agglutination with 
polyvalent somatic (O) antigen grouping sera, followed, in some cases, by testing 
with monovalent antisera for specific serotype identification. Monovalent antiserum 
to S. dysenteriae 1 is required to identify this serotype, which is the most frequent 
cause o f severe epidemic dysentery. Once one colony from a plate has been 
identified as Shigella, no further colonies from the same specimen need to be tested.
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F ig u re  4-10. A pink 
color deve lop s  in a 
positive u re a se  
reaction ( tube on left)
F ig u re  4-11. O rg an ­
ism s positive for lysine 
decarbo x y lase  produce 
a  purple color th rough­
out th e  LIA medium 
(tube on right). 
Lysine-negative 
o rgan ism s  p roduce a 
yellow color (acid) in 
th e  butt portion of the 
tu b e  (tube on left).
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Laboratorians should be aware that some Shigella commercial antiserum is 
labeled or packaged differently; for example, Shigella polyvalent A, which 
includes antisera to serotypes 1 through 7, may also be labeled polyvalent A1. 
Also, monovalent antiserum may be labeled in a way that it may be confused with 
polyvalent antiserum; for example, monovalent antiserum to S. dysenteriae 1 
may be labeled “Shigella  A1” instead o f “S. dysenteriae serotype 1”. When 
using newly purchased antisera, the laboratorian should read the package insert 
or check with the manufacturer if  the label is not self-explanatory.
1. Slide agglutination
Because S. dysenteriae 1 (followed by S. flexneri and S. sonnei) is the most 
common agent o f epidemic dysentery, isolates that react typically in the 
screening biochemicals should be screened first with monovalent A1 antiserum, 
then with polyvalent B antiserum, and finally in polyvalent D antiserum.
Agglutination tests may be carried out in a petri dish or on a clean glass slide. 
An inoculating loop or needle, sterile applicator stick or toothpick is used to 
remove a portion o f the growth from the surface o f KIA, TSI, heart infusion agar 
(HIA), or other nonselective agar medium. Serologic testing should not be done 
on growth from selective media such as MAC or XLD because this may give 
false-negative results. Emulsify the growth in two small drops o f physiological 
saline and mix thoroughly. Add a small drop o f antiserum to one o f the suspen­
sions. Usually approximately equal volumes o f antiserum and growth suspension 
are mixed, but the volume o f suspension may be as much as double the volume of 
the antiserum. To conserve antiserum, volumes as small as 10 microliters can be 
used. An inoculating loop may be used to dispense small amounts of antisera if  
micropipettors are not available (Figure 4-12). Mix the suspension and antiserum 
well and then tilt the slide back and forth to observe for agglutination. If the 
reaction is positive, clumping will appear within 30 seconds to 1 minute (Figure 
4-13). Examine the saline suspension carefully to ensure that it is even and does 
not show clumping due to autoagglutination. If autoagglutination occurs, the 
culture is termed “rough” and cannot be serotyped.
Cultures that react serologically and show no conflicting results in the bio­
chemical screening tests are reported as positive for Shigella. Serologically 
negative isolates that are biochemically identified as Shigella may be sent to a 
reference laboratory.
2. Quality control of antisera
All lots o f antisera should be quality controlled before use. Quality control of  
antisera is discussed in Chapter 11.
D. Media for Isolation and Identification of Shigella
This section contains descriptions o f all media mentioned in this chapter and 
discussions of their characteristics, preparation, and appropriate quality control 
strains. Each manufacturer’s lot number of commercial dehydrated media or each
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F ig u re  4-12. A bent loop m ay be  helpful in d ispensing small am o u n ts  of an tiserum  
for slide agglutination tests .
F ig u re  4-13. Shigella an t ise rum  will agglutinate s trains of the  s a m e  se rogroup  or 
se ro type  (right). Shigella will not agglutinate w h en  mixed with saline (left).
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batch o f media prepared from individual ingredients should be quality controlled 
before use. See Chapter 11 for a description o f appropriate quality control 
methods.
1. Desoxycholate citrate agar
Desoxycholate citrate agar (DCA) is a differential selective plating medium for 
the isolation o f enteric pathogens, particularly Shigella and Salm onella. Lactose- 
fermenting organisms produce pink colonies surrounded by a zone o f bile precipi­
tation. Colonies o f lactose-nonfermenting strains are colorless. Several formula­
tions o f DCA, which may vary in selectivity, are available from different manu­
facturers.
Preparation and  qua lity  control
Prepare according to manufacturer’s instructions. [Note: It may also be 
prepared from individual ingredients, but this can result in much greater lot-to-lot 
variation than when prepared from commercial dehydrated preparations.] DCA 
medium is very heat-sensitive, and overheating during boiling should be avoided. 
Do not autoclave. Plates can be stored at 4°C for up to a week.
For quality control of DCA, the following organisms should be adequate for 
confirmation of selective and inhibitory growth characteristics: E. coli may be 
somewhat inhibited, depending on the particular formulation used, but will 
produce pink colonies surrounded by a zone o f precipitated bile; S. flexneri and 
S. dysenteriae 1 will produce fair to good growth o f colorless colonies.
2. Hektoen enteric agar
Hektoen enteric agar (HE) is a differential selective agar that is useful for 
isolation o f Salm onella and Shigella. It has an H2S-indicator system for selecting 
H2S-producing Salm onella, which produce blue-green colonies with a black 
center. Shigella  colonies are green while rapid lactose-fermenters such as E. coli 
are pink to orange with a zone o f bile precipitation.
Preparation and  qua lity  control
Prepare according to manufacturer’s instructions. [Note: Several commercial 
brands o f HE are available. This medium can also be prepared from individual 
ingredients, but results may be much more variable than with a commercial 
dehydrated formulation.] Heat to boiling to dissolve, but avoid overheating. Do 
not autoclave. When cool enough to pour, dispense into plates. Plates can be 
stored at 4°C for up to 1 week.
For quality control o f HE, the following organisms should be adequate for 
confirmation o f selective and inhibitory growth characteristics: E. coli should 
produce colonies that are pink to orange surrounded by a bile precipitate;
S. flexneri should produce fair to good growth o f green colonies, but 
S. dysenteriae 1 colonies should be smaller.
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3. Kligler iron agar and triple sugar iron agar
Kligler iron agar (KIA) and triple sugar iron (TSI) agar are carbohydrate- 
containing screening media widely used for identification of enteric pathogens, 
including Shigella . Both media differentiate lactose fermenters from 
nonfermenters and have a hydrogen sulfide indicator. H2S-producing organisms 
will cause blackening o f the medium in both KIA and TSI.
KIA contains glucose and lactose. Organisms which ferment glucose cause the 
butt o f the tube to become acid (yellow); some also produce gas. Lactose- 
fermenting organisms will produce an acid (yellow) slant; lactose-nonfermenting 
organisms will have an alkaline (red) slant.
TSI contains sucrose in addition to the ingredients in KIA. Organisms which 
ferment either lactose or sucrose will produce an acid (yellow) slant while 
organisms that ferment neither carbohydrate will have an alkaline (red) slant. As 
in KIA, glucose-fermenters produce an acid (yellow) reaction in the butt (some­
times with gas produced).
Preparation and  qua lity  control
Prepare according to manufacturer’s instructions. [Note: There are several 
commercially available dehydrated formulations o f KIA and TSI. These media 
can also be prepared from individual ingredients, but there may be lot-to-lot 
variation.] Dispense a quantity o f medium in appropriate containers such that the 
volume o f medium is sufficient to give a deep butt and a long slant. For example, 
dispense 6.5 ml of medium into 16 x 125-mm screw-cap tubes (leave caps loose), 
and after autoclaving allow the slants to solidify in a manner such that the medium 
in the butt o f the tube is about 3.5 cm deep and the slant is about 2.5 cm long. 
Tighten caps and store at 4°C for up to 6 months.
For quality control of KIA or TSI, the following organisms should be adequate 
for confirmation o f biochemical response characteristics: E. coli should give an 
acid slant and butt, with the production o f gas but no H2S; S. flexneri should give 
an alkaline slant, acid butt, without production o f gas or H2S (Figure 4-8); an 
H2S-producing Salm onella may be used to control this reaction.
4. Lysine iron agar
Organisms that produce lysine decarboxylase in LIA cause an alkaline reaction 
(purple color) in the butt o f the medium and also on the slant (Figure 4-11). H2S 
production is indicated by a blackening o f the medium. Organisms lacking lysine 
decarboxylase, such as Shigella , typically produce an alkaline slant (purple) and 
an acid butt (yellow) no gas, and no H2S (Table 4-2). Proteus and Providencia 
spp. will often produce a red slant caused by deamination o f the lysine. LIA must 
be prepared so that the volume o f medium in the tube is sufficient to give a deep 
butt. It is important for LIA tubes to have a deep butt because the decarboxyla­
tion reaction occurs only in anaerobic conditions.
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Preparation and  qua lity  control
Prepare medium according manufacturer’s instructions on the bottle. [Note: 
Several companies sell dehydrated LIA. LIA may also be prepared from indi­
vidual ingredients, but there may be lot-to-lot variation.] Dispense a quantity o f 
medium in appropriate containers such that the volume o f medium is sufficient to 
give a deep butt and a long slant. For example, dispense 6.5 ml o f medium into 16 
x 125-mm screw-cap tubes (leave caps loose), and after autoclaving allow the 
slants to solidify in a manner such that the medium in the butt o f the tube is 3.5 cm 
deep and the slant is 2.5 cm long. Tighten caps and store at 4°C for up to 6 
months.
For quality control o f LIA, the following organisms may be used: S. flexneri 
should produce an alkaline slant and an acid butt without production o f H2S; an 
H2S-producing Salm onella strain may be used to control the H2S reaction and will 
most likely be lysine-positive and give an alkaline reaction in the butt of the tube.
5. MacConkey agar
MacConkey agar (MAC) is a differential plating medium recommended for use 
in the isolation and differentiation of lactose-nonfermenting, gram-negative enteric 
bacteria from lactose-fermenting organisms. Colonies o f Shigella  on MAC 
appear as convex, colorless colonies about 2 to 3 mm in diameter. S. dysenteriae 
1 colonies may be smaller.
Several commercial brands o f MAC are available. Most manufacturers 
prepare several formulations o f MAC, which may vary in selectivity and thereby 
affect the isolation o f Shigella. For example, some formulations o f MAC do not 
contain crystal violet, a selective agent; these types are not as selective and should 
not be used for isolation o f Shigella. Oxoid MacConkey Agar No. 3, Difco Bacto 
MacConkey Agar, and BBL MacConkey Agar are all suitable.
P reparation and  qua lity  control
Prepare according to manufacturer’s instructions. [Note: MAC can also be 
prepared from individual ingredients, but this produces much more variable results 
than a commercial dehydrated formulation.] Sterilize by autoclaving at 121°C for 
15 minutes. Cool to 50°C and pour into petri plates. Leave lids ajar for about 20 
minutes so that the surface o f the agar will dry. Close lids and store at 4°C for up 
to 1 month. If plates are to be stored for more than a few days, put them in a 
sealed plastic bag to prevent drying.
For quality control o f MAC, the following organisms should be adequate for 
confirmation o f selective and inhibitory growth characteristics: E. coli should 
produce pink to red colonies with good to excellent growth; S. flexneri should 
produce colorless colonies with fair to good growth, but S. dysenteriae 1 colonies 
may be smaller.
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6. Motility medium
Because Shigella  spp. are always nonmotile, motility medium is a useful 
biochemical screening test. Motility is indicated by the presence o f diffuse growth 
(appearing as clouding o f the medium) away from the line o f inoculation (Figure 
4-9). Nonmotile organisms do not grow out from the line of 
inoculation.
Preparation and  qua lity  control
Follow manufacturer’s instructions to weigh out and suspend dehydrated 
medium. [Note: Several commercial dehydrated formulations o f motility agar are 
available. This medium can also be prepared from individual ingredients.] Heat 
to boiling to make sure medium is completely dissolved. Dispense into tubes or 
other types o f containers, leaving caps loose, and sterilize at 121°C for 15 min. 
Allow to solidify upright, forming a deep butt with no slant (e.g., about 4 to 5 ml 
of medium per 13 x 100-mm screw-cap tube). When the medium is solidified and 
cooled, leave caps loose until the surface o f the medium has dried. Tighten caps 
and store at 4°C for up to 6 months.
For quality control o f motility medium, the following organisms may be used:
E. coli is motile, while Shigella spp. are nonmotile. The surface o f the medium 
should be dry when used. If moisture has accumulated in the tube, carefully pour 
it out before inoculating the tube. Moisture can cause a nonmotile organism to 
grow down the sides o f the agar creating a haze o f growth and appearing to be 
motile.
7. Sulfide-indole-motility medium
Sulfide-indole-motility medium (SIM) is a commercially available combination 
medium that combines three tests in a single tube: hydrogen sulfide (H2S) 
production, indole production, and motility. The indole reaction is not useful for 
screening suspected Shigella  isolates because strains vary in their reactions in this 
test. It is inoculated in the same way as motility agar, by using a needle to stab 
about 1 to 2 cm down into the medium, and is incubated overnight at 35° to 37°C. 
The motility reaction is read the same as for motility medium. As in KIA or TSI, 
H2S production is indicated by blackening o f the medium. Indole production can 
be tested by either the filter paper method or by adding Kovac’s reagent to the 
tube.
Preparation and  qua lity  control
Follow manufacturer’s instructions to weigh out and suspend dehydrated 
medium. Heat to boiling to make sure the medium is completely dissolved. 
Dispense into tubes and sterilize by autoclaving for 15 minutes at 121°C.
For quality control o f SIM medium, the following organisms may be used:
E. coli is indole positive, H2S negative, and motility positive; an H2S-producing 
Salm onella strain may be used to control the H2S reaction and will most likely be
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motile and indole negative; Shigella  spp. are motility negative and H2S negative 
but are variable for the indole reaction.
8. Urea medium
Urease-positive cultures produce an alkaline reaction in the medium, 
evidenced by a pinkish-red color (Figure 4-10). Urease-negative organisms do 
not change the color o f the medium, which is a pale yellowish-pink. Shigella spp. 
are always urease-negative (Table 4-2).
P reparation and  qua lity  control
Follow manufacturer’s instructions for preparation. [Note: Several 
commercial brands o f urea medium are available, some o f which require the 
preparation o f a sterile broth which is added to an autoclaved agar base. Some 
manufacturers have sterile prepared urea concentrate available for purchase.]
Prepare urea agar base as directed on the bottle. Sterilize at 121°C for 15 min. 
Cool to 50° to 55°C, then add urea concentrate according to manufacturer’s 
directions. Before adding the urea to the agar base, make sure the agar base is 
cool since the urea is heat labile. Mix and distribute in sterile tubes. Slant the 
medium so that a deep butt is formed.
For quality control o f urea medium, the following organisms may be used: 
Proteus spp. produce urease; E. coli is urease negative.
9. Xylose lysine desoxycholate agar
Xylose lysine desoxycholate agar (XLD) is a selective differential medium 
suitable for isolation o f Shigella and Salm onella from stool specimens. 
Differentiation o f these two species from nonpathogenic bacteria is 
accomplished by xylose and lactose fermentation, lysine decarboxylation, and 
hydrogen sulfide production.
Shigella  colonies on XLD agar are transparent pink or red smooth colonies 1 to 
2 mm in diameter (Figure 4-5). S. dysenteriae 1 colonies on XLD agar are 
frequently very tiny, unlike other Shigella  species (Figure 4-4). Coliforms appear 
yellow (4-6). Salm onella colonies are usually red with black centers but may be 
yellow with black centers.
Preparation and  qua lity  control
Prepare according to manufacturer’s instructions. [Note: Several commercial 
brands o f XLD agar are available. This medium can also be prepared from 
individual ingredients, but results may be much more variable than with a com­
mercial dehydrated formulation.] Mix thoroughly. Heat with agitation just until 
the medium boils. Do not overheat; overheating when boiling XLD or allowing 
the medium to cool too long may cause the medium to precipitate. Cool flask 
under running water until just cool enough to pour. Avoid cooling the medium too 
long. Pour into petri plates, leaving the lids ajar for about 20 minutes so that the
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surface of the agar will dry. Plates can be stored at 4°C for up to a week.
For quality control o f XLD, the following organisms should be adequate for 
confirmation o f selective and inhibitory growth characteristics: S. flexneri should 
produce fair to good growth o f transparent pink or red smooth colonies that are 1 
to 2 mm in diameter; S. dysenteriae 1 may produce very small transparent or red 
colonies; E. coli should produce poor to fair growth o f yellow colonies.
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Chapter 5 
Etiology and Epidemiology of Cholera
Isolates o f Vibrio choJerae serogroup O1 are classified into two biotypes, El 
Tor and classical, on the basis o f several phenotypic characteristics. Currently, 
the El Tor biotype is responsible for virtually all o f the cholera cases throughout 
the world, and classical isolates are not encountered outside of Bangladesh. In 
addition V choJerae O1 is classified into two serotypes, Inaba and Ogawa, based 
on agglutination in antiserum. A possible third serotype, Hikojima, has been 
described, but it is very rare. During an outbreak or epidemic, it is worth docu­
menting the biotype and serotype o f the isolate; however, it is not 
necessary to know this information to respond appropriately to the epidemic.
Within the O1 and O139 serogroups, the ability to produce cholera toxin (CT) 
is a major determinant o f virulence. In general, isolates o f V. choJerae O1 or 
O139 that produce CT are considered fully virulent and capable o f causing 
epidemic cholera (Table 5-1). Most V. choJerae isolated during cholera 
outbreaks will be toxigenic serogroup O1 or O139. However, some isolates o f V 
choJerae O1 do not produce CT and cannot cause epidemic cholera. When these 
isolates are encountered, they must be considered within their clinical and epide­
miologic context. Nontoxigenic isolates may be associated with sporadic diarrheal 
disease.
A. Historical Background
Cholera is thought to have its ancestral home in the Ganges Delta o f the Indian 
subcontinent. In the nineteenth century, pandemic waves o f cholera spread to 
many parts of the world. In 1961, a massive epidemic began in Southeast Asia; 
this is now recognized as the beginning o f the seventh cholera pandemic. This 
pandemic was caused by the El Tor biotype o f toxigenic 
V. choJerae O1. It spread rapidly through south Asia, the Middle East, and 
southeastern Europe, reaching Africa by 1970. In January 1991, epidemic cholera 
appeared in South America in several coastal cities of Peru and spread rapidly to 
adjoining countries. By the end o f 1996, cholera had spread to 21 countries in 
Latin America, causing over 1 million cases and nearly 12,000 deaths. The 
number o f cholera cases reported elsewhere in the world has also increased in the 
1990s. In Africa in the early 1990s, the primary focus o f cholera was in southern 
Africa. However, in the latter part o f the decade, the focus moved to west Africa. 
Overall, more cases were reported from Africa in the 1990s than in a similar time 
period in previous decades.
Vibrio cholerae serogroup O139
Vibrio choJerae serogroup O139 appeared in India in late 1992. It quickly 
spread to Bangladesh and other Asian countries, although the rate o f spread has 
slowed after the initial outbreaks. Through 1998, 11 countries have officially
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reported transmission o f V choJerae O139 to WHO. Imported cases have been 
reported from the United States and other countries. At this time, V. choJerae 
O139 appears to be confined to Asia.
T ab le  5-1. C om parison  of epidemic- and non -ep idem ic-associa ted  
V cholerae s tra ins
Typing systems Epidemic-associated Non-epidemic-associated
Serogroups Ü i, Ü i39 Non-O1 (>150 exist)
Biotypes for serogroup Ü i Classical and El Tor 
(not applicable to 
serogroup Ü i39)
Biotypes are not 
applicable to 
non-O1 strains
Serotypes for serogroup Ü i Inaba, Ügawa, and 
Hikojima (not applicable 
to serogroup Ü i39)
These 3 serotypes are not 
applicable to non-O1 
strains
Toxin production Produce cholera toxina Usually do not produce 
cholera toxin; sometimes 
produce other toxins
a Nontoxigenic O1 strains exist but are rarely associated with epidemics.
The epidemiologic characteristics o f the O139 serogroup are similar to those of 
the O1 serogroup. The isolation and identification characteristics of the O139 
serogroup are identical to those o f the O1 serogroup except that O139 antiserum 
is needed for identification. Biotyping tests for V cholerae O1 are not valid for V 
cholerae O139 or any non-O1/O139 serogroup.
B. Clinical Manifestations
Cholera is a secretory diarrheal disease. The enterotoxin produced by 
V. cholerae O1 and O139 causes a massive outpouring o f fluid and electrolytes 
into the bowel. This rapidly leads to profuse watery diarrhea, loss o f circulation 
and blood volume, metabolic acidosis, potassium depletion, and ultimately 
vascular collapse and death. In severe cases, purging diarrhea can rapidly cause 
the loss o f 10% or more o f the body’s weight, with attendant hypovolemic shock 
and death; however, 75% or more o f initial infections with V. cholerae O1 or 
O139 may be asymptomatic, depending on the infecting dose. Of the 25% of 
persons with symptomatic infections, most have mild illness. Approximately 5% 
o f patients have moderate illness that requires medical attention but not hospital­
ization. In only about 2% o f patients does the illness progress to life-threatening 
“cholera gravis.” Persons with blood type O are more likely to develop severe 
cholera than those with other blood types.
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C. Treatment
Successful treatment o f cholera patients depends on rapid replacement o f fluid 
and electrolyte losses. With proper treatment, mortality is less than 1% of 
reported cases. Fluids and electrolytes can be replaced rapidly through either oral 
or intravenous routes. Intravenous therapy is required for patients who are in 
profound shock or cannot drink.
Antimicrobial therapy is helpful, although not essential, in treating cholera 
patients. Antimicrobial agents reduce the duration o f illness, the volume o f stool, 
and the duration o f shedding o f vibrios in the feces. When antimicrobial agents 
are used, it is essential to choose one to which the organism is susceptible. 
Antimicrobial agents recommended by WHO for treating cholera patients include 
tetracycline, doxycycline, furazolidone, trimethoprim-sulfamethoxazole, erythro­
mycin, or chloramphenicol. Ciprofloxacin and norfloxacin are also effective. 
Because antimicrobial resistance has been a growing problem in many parts o f the 
world, the susceptibility o f V. choJerae O1 strains to antimicrobial agents should 
be determined at the beginning o f an epidemic and be monitored periodically (see 
Annexes C and E).
For V. choJerae, the results o f disk diffusion tests for ampicillin, sulfonamides, 
tetracycline, and trimethoprim-sulfamethoxazole (i.e., percentage o f susceptible, 
intermediate, and resistant) correlate well with the minimum inhibitory concentra­
tion (MIC) results determined by broth microdilution. Disk diffusion tests should 
not be used for doxycycline and erythromycin because the results for these drugs 
are frequently inaccurate for V. choJerae O1 and O139 strains. However, the 
tetracycline disk test can be used to predict the likely susceptibility o f isolates to 
doxycycline. Additional details on antimicrobial susceptibility testing are given in 
Chapter 9.
D. Epidemiology
When cholera first appears in epidemic form in an unexposed population, it can 
affect all age groups. In contrast, in areas with high rates o f endemic disease, 
most of the adult population have gained some degree o f natural immunity 
because of illness or repeated asymptomatic infections. In this setting, the disease 
occurs primarily in young children, who are exposed to the organism for the first 
time, and in the elderly, who have lower gastric acid production and waning 
immunity. The poor are at greatest risk because they often lack safe water 
supplies, are unable to maintain proper hygiene within the home, and may depend 
on street vendors or other unregulated sources for food and drink.
Numerous investigations have linked cholera transmission to drinking water 
drawn from shallow wells, rivers or streams, and even to bottled water and ice. 
Food is the other important means o f cholera transmission. Seafood has repeat­
edly been a source o f cholera, particularly raw or undercooked shellfish harvested 
from sewage-contaminated beds or from environments where 
V. choJerae O1 occurs naturally. Although V. choJerae O1 and O139 are easily 
killed by drying, sunlight, and acidity, they grow well on a variety o f moist
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alkaline foods from which other competing organisms have been eliminated by 
previous cooking. Cooked rice is an excellent growth medium, as are lentils, 
millet, and other cooked grains and legumes with neutral pH. Fruits and veg­
etables grown in sewage and eaten without cooking or other decontaminating 
procedures are potential vehicles o f cholera transmission. Freezing foods or 
drinks does not prevent cholera transmission.
Person-to-person spread through direct contact, as by shaking hands or touch­
ing or by taking care of a patient, has not been shown to occur. Outbreaks on 
crowded hospital wards are likely to be due to contaminated food or water. 
Likewise, outbreaks following the funeral o f a cholera patient have been caused 
by eating contaminated foods served at the wake, often prepared by the same 
persons who prepared the body for burial.
E. Cholera Vaccine
During the past 15 years, considerable progress has been made in the develop­
ment o f new oral vaccines against cholera. Two oral cholera vaccines, which 
have been evaluated with volunteers from industrialized countries and in regions 
with endemic cholera, are commercially available in several countries: a killed 
whole-cell V. choJerae O1 in combination with purified recombinant B subunit of  
cholera toxin (WC/rBS); and an attenuated live oral cholera vaccine, containing 
the genetically manipulated V. choJerae O1 strain CVD 103-HgR. The appear­
ance o f V. choJerae O139 has redirected efforts to develop an effective and 
practical cholera vaccine. None o f the currently available vaccines is effective 
against this strain.
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Chapter 6 
Isolation and Identification of Vibrio cholerae 
Serogroups O1 and O139
Isolation and identification o f V choJerae serogroups O1 and O139 can be 
greatly enhanced when optimal laboratory media and techniques are employed. 
The methods presented here are intended to be economical and to offer 
laboratorians some flexibility in choice o f protocol and media. Laboratories that 
do not have sufficient resources to adopt the methods described in this chapter 
should consider sending the specimens or isolates to other laboratory facilities 
that routinely perform these procedures.
A. Isolation Methods
Before 1992, o f the more than 150 serogroups o f Vibrio choJerae that have 
been reported, only the O1 serogroup was associated with epidemic and 
pandemic cholera. However in late 1992 and early 1993, large outbreaks of 
cholera due to a newly described serogroup, O139, were reported in India and 
Bangladesh. This strain, like serogroup O1 V. choJerae, produces cholera 
enterotoxin. Because the cultural and biochemical characteristics o f these two 
serogroups are identical, the isolation and identification methods described 
below apply to both O1 and O139. Both serogroups must be identified using 
O-group-specific antisera. Annex A  lists diagnostic supplies necessary for 
laboratory confirmation and antimicrobial susceptibility testing o f V. choJerae.
Although V. choJerae will grow on a variety o f commonly used agar media, 
isolation from fecal specimens is more easily accomplished with specialized 
media. Alkaline peptone water (APW) is recommended as an enrichment broth, 
and thiosulfate citrate bile salts sucrose agar (TCBS) is the selective agar 
medium o f choice (Figure 6-1). In certain instances (for example, when the 
patient is in very early stages o f illness), it may not be necessary to enrich 
specimens or use selective plating media. However, enrichment broth and a 
selective plating medium should always be used with convalescent patients, 
suspected asymptomatic infections, environmental specimens, and whenever 
high numbers o f competing organisms are likely to be present in the specimen.
Refer to Section C, “Media and Reagents for V. choJerae,” before preparing 
any of these media because incorrect preparation can affect the reactions of 
organisms in these tests. Chapter 11 discusses methods for quality control of 
selective media and antisera.
1. Enrichment in alkaline peptone water
Enrichment in APW can enhance the isolation of V. choJerae when few  
organisms are present, as in specimens from convalescent patients and asymp­
tomatic carriers. Vibrio spp. grow very rapidly in APW, and at 6 to 8 hours will 
be present in greater numbers than non-Vibrio organisms.
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O p tiona l :  
A P W  E n r i c h m e n t  
6 -8  hr, 3 5 ° -3 7 °  C*
O p tiona l:
N o n s e le c t iv e  a g a r ------- ► O x i d a s e
+
V. cho lerae  0 1  





O g a w a  a n d  I n a b a V. cho lerae  0 1 3 9
S e r o lo g y S e r o lo g y
+ fo r  e i th e r + l
Antim icrob ia l  
su sc ep t ib i l i ty  t e s t
* If the  A P W  canno t  be s t reaked  after 6-8 hours of incubation, 
subcu lture at  18 hours  to a  fresh tu b e  of APW; incubate for 6-8 hours, 
an d  then  s t reak  to TCBS
F ig u re  6-1. P ro ced u re  for recovery of Vibrio cholerae O1 an d  O 139 from fecal 
sp ec im e n s
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APW can be inoculated with liquid stool, fecal suspension, or a rectal swab. 
The stool inoculum should not exceed 10% of the volume o f the broth. Incubate 
the tube with the cap loosened at 35° to 37°C for 6 to 8 hours. After incubation, 
subculture to TCBS should be made with one to two loopfuls o f APW  
from the surface and topmost portion o f the broth, since vibrios preferentially 
grow in this area. Do not shake or mix the tube before subculturing. If the 
broth cannot be plated after 6 to 8 hours o f incubation, subculture a loopful at 
18 hours to a fresh tube o f APW. Subculture this second tube to TCBS agar 
after 6 to 8 hours o f incubation (Figure 6-1).
2. Isolation from TCBS selective agar
TCBS agar is commercially available and easy to prepare, requires no auto­
claving, and is highly differential and selective (see Section C). Growth on this 
medium is not suitable for direct testing with V. choJerae antisera.
Inoculation of TCBS
Figure 6-1 outlines the procedure for isolation o f V. choJerae from fecal 
specimens. Inoculate the TCBS plate as described in Chapter 4 (Figure 4-2). 
After 18 to 24 hours’ incubation at 35° to 37°C, the amount and type o f growth 
(e.g., sucrose-fermenting or sucrose-nonfermenting) on the TCBS plate should 
be recorded on data sheets (Figure 6-2). Colonies suspicious for V. choJerae 
will appear on TCBS agar as yellow, shiny colonies, 2 to 4 mm in diameter 
(Figure 6-3). The yellow color is caused by the fermentation o f sucrose in the 
medium. Sucrose-nonfermenting organisms, such as V. parahaemoJyticus, 
produce green to blue-green colonies.
Isolation of suspected V cholerae
Carefully select at least one o f each type o f sucrose-fermenting colony from 
the TCBS plate to inoculate a heart infusion agar (HIA) slant or another nonse- 
lective medium. Do not use nutrient agar because it has no added salt and does 
not allow optimal growth of V. choJerae. Using an inoculating needle, lightly 
touch only the very center o f the colony. Do not take the whole colony or go 
through the colony and touch the surface o f the plate. This is to avoid picking 
up contaminants that may be on the surface o f the agar. If there is doubt that a 
particular colony is sufficiently isolated from surrounding colonies, purify the 
suspicious colony by streaking on another agar plate.
Incubate the HIA slants at 35° to 37°C for up to 24 hours; however, there 
may be sufficient growth at 6 hours for serologic testing to be done. Slide 
serology with polyvalent O1 and O139 antisera is sufficient for a presumptive 
identification (see section B below for a description o f serologic identification).
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aSUC + = Sucrose-positive colonies bSUC - = Sucrose-negative colonies
Figure 6-2. Vibrio cholerae w o rk shee t
Isolation and Identification o/Vibrio cholerae Serogroups 01 and 0139
Isolation and Identification o f  Vibrio cholerae Serogroups O1 and O139
F ig u re  6-3. Grow th of V. cholerae on TCBS
F ig u re  6-4. A positive ox id ase  te s t  (show n here) resu lts  in th e  deve lo p m en t of a 
dark  purple color within 10 seco n d s . V. cholerae is ox id ase  positive.
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3. Screening tests for suspected V. cholerae isolates
Generally for suspected V cholerae isolates from fecal specimens, screening 
with biochemical tests prior to testing with O1 and O139 antisera is not necessary. 
However, if  the supply o f antisera is limited, the oxidase test may be useful for 
additional screening o f isolates before testing with antisera.
O xidase test
Conduct the oxidase test with fresh growth from an HIA slant or any non­
carbohydrate-containing medium. Do not use growth from TCBS agar because it 
may yield either false-negative or false-positive results. Place 2 to 3 drops of  
oxidase reagent (1% N,N,N',N'-tetramethyl-p-phenylenediamine) on a piece o f 
filter paper in a petri dish. Smear the culture across the wet paper with a platinum 
(not nichrome) loop, a sterile wooden applicator stick or toothpick. In a positive 
reaction, the bacterial growth becomes dark purple immediately (Figure 6-4). 
Oxidase-negative organisms will remain colorless or will turn purple after 10 
seconds. Color development after 10 seconds should be disregarded. Positive and 
negative controls should be tested at the same time. Organisms o f the genera 
Vibrio (including V. cholerae, Table 6-1), N eisseria, Campylobacter, Aeromonas, 
Plesiomonas, Pseudom onas, and Alcaligenes are all oxidase positive; all Entero- 
bacteriaceae are oxidase negative.
T ab le  6-1. R eac tion s  of V. cholerae in sc reen in g  te s ts
Screening test Vibrio cholerae reactions
Oxidase test Positive
String test Positive
KIA K/A, no gas produced (red slant/yellow butt)a
TSI A/A, no gas produced (yellow slant/yellow butt)a
LIA K/K, no gas produced (purple slant/purple butt)a,b
Gram stain Small, gram-negative curved rods
Wet mount Small, curved rods with darting motility
■ K = alkaline; A = acid
b An alkaline reaction (purple) in the butt of the medium indicates that lysine was decarboxylated.
An acid reaction (yellow) in the butt of the medium indicates that lysine was not decarboxylated.
Additional biochemical screening tests
The string reaction, Kligler iron agar (KIA) or triple sugar iron agar (TSI), 
lysine iron agar (LIA), Gram stain, and wet mount for motility are other possible 
tests that may be used for additional screening o f isolates before testing with 
antisera (Table 6-1). The value o f these tests should be assessed to determine 
their usefulness before they are applied routinely. See Section C for instructions 
on preparation o f media and appropriate quality control strains.
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S trin g  test
The string test, using fresh growth from nonselective agar, is useful for ruling 
out non- Vibrio spp., particularly Aerom onas spp. The string test may be per­
formed on a glass microscope slide or plastic petri dish by suspending 18- to 24- 
hour growth from HIA or other noninhibitory medium in a drop o f 0.5% aqueous 
solution o f sodium deoxycholate. If the result is positive, the bacterial cells will 
be lysed by the sodium deoxycholate, the suspension will lose turbidity, and DNA  
will be released from the lysed cells, causing the mixture to become viscous. A  
mucoid “string” is formed when an inoculating loop is drawn slowly away from 
the suspension (Figure 6-5). V. cholerae (Table 6-1) strains are positive, whereas 
Aerom onas strains are usually negative. Other Vibno spp. may give a positive or 
weak string test reaction.
F ig u re  6-5. A positive 
string test with 
V. cholerae
K iigier iron  agar and  tripie sugar iron  agar
Kligler iron agar (KIA) and triple sugar iron agar (TSI) can be used to rule out 
Pseudom onas spp. and certain Enterobacteriaceae. The reactions o f V. cholerae 
on KIA, which contains glucose and lactose, are similar to those o f lactose- 
nonfermenting Enterobacteriaceae (alkaline (red) slant, acid (yellow) butt, no 
gas, no H2S) (see Table 6-1 and Figure 6-6). However, on TSI, V. cholerae
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strains produce an acid (yellow) slant and acid (yellow) butt, no gas, and no H2S.
KIA or TSI slants are inoculated by stabbing the butt and streaking the surface 
o f the medium. Incubate the slants at 35° to 37°C and examine after 18 to 24 
hours. Caps on all tubes o f biochemicals should be loosened before incubation, 
but this is particularly important for KIA or TSI slants. If the caps are too tight 
and anaerobic conditions exist in the KIA or TSI tube, an inappropriate reaction 
will occur and the characteristic reactions o f V cholerae may not be exhibited.
F ig u re  6-6. R eac tions of V. cholerae in Kiigier iron a g a r  (left) 
an d  triple su g a r  iron a g a r  (right)
L ysine iron  agar
LIA is helpful for screening out Aerom onas and certain Vibrio spp., which, 
unlike V. cholerae, do not decarboxylate lysine. LIA is inoculated by stabbing the 
butt and streaking the slant. After incubation for 18 to 24 hours at 35° to 37°C, 
examine the LIA slants for reactions typical o f V. cholerae. Organisms that 
produce lysine decarboxylase in LIA cause an alkaline reaction (purple color) in 
the butt o f the tube (see Chapter 4, Figure 4-11). Organisms without the enzyme
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produce a yellow color (acid) in the butt portion of the tube. H2S production is 
indicated by a blackening o f the medium. The LIA reaction for V cholerae is 
typically an alkaline slant (purple), alkaline butt (purple), no gas, and no H2S 
(Table 6-1). Proteus and Providencia spp. will often produce a red slant caused 
by deamination o f the lysine.
It is important that KIA, TSI, and LIA be prepared so the tubes have a deep 
butt and a long slant. If the butt is not deep enough, misleading reactions may 
occur in these media. In LIA, the decarboxylation o f lysine occurs only in 
anaerobic conditions and a false-negative reaction may result from insufficient 
medium in the tube (Section C).
Gram stain
Examining overnight growth from an HIA slant by Gram stain will demon­
strate typical small, curved gram-negative rods (Table 6-1). Staining with crystal 
violet only is a more rapid technique and will still demonstrate the cell morphol­
ogy typical of Vibrio spp.
Wet m o un t
Dark-field and phase-contrast microscopy have been used for screening 
suspected isolates o f V. cholerae. With these techniques, saline suspensions are 
microscopically examined for the presence o f organisms with typical small, 
curved rods and darting (“shooting star”) motility (Table 6-1).
B. Serologic Identification of V. cholerae O1 and O139
1. Presumptive identification using O1 and O139 antisera
For slide agglutination testing with polyvalent O1 or O139 antisera, fresh 
growth o f suspected V. cholerae from a nonselective agar medium should be used. 
Using growth from TCBS agar may result in false-negative reactions. Usually 
after 5 to 6 hours o f incubation, growth on the surface o f the slant is sufficient to 
perform slide serology with antisera; if  not, incubate for a longer period. If the 
isolate does not agglutinate in O1 antiserum, test in O139 antiserum. If it is 
positive in the polyvalent O1 or in the O139 antiserum, it may be reported as 
presumptive V. cholerae O1 or O139. Presumptive V. cholerae O1 isolates 
should be tested in monovalent Ogawa and Inaba antisera (see below). Once one 
colony from a plate has been identified as V. cholerae O1 or O139, no further 
colonies from the same plate need to be tested.
2. Confirmation of V cholerae O1 using Inaba and Ogawa antisera
The O1 serogroup o f V. cholerae has been further divided into three serotypes, 
Inaba, Ogawa, and Hikojima (very rare). Serotype identification is based on 
agglutination in monovalent antisera to type-specific O antigens (see Table 6-2). 
A positive reaction in either Inaba or Ogawa antiserum is sufficient to confirm the 
identification o f a V. cholerae O1 isolate. Isolates that agglutinate weakly or 
slowly with serogroup O1 antiserum but do not agglutinate with either Inaba or
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Ogawa antiserum are not considered to be serogroup O1. Identifying these 
antigens is valid only with serogroup O1 isolates. For this reason, Inaba and 
Ogawa antisera should never be used with strains that are negative with poly­
valent O1 antiserum.
Strains o f one serotype frequently produce slow or weak agglutination in 
antiserum to the other serotype, depending on how well the serotype-specific 
antisera have been absorbed. For this reason, agglutination reactions with Inaba 
and Ogawa antisera should be examined simultaneously, and the strongest and 
most rapid reaction should be used to identify the serotype. With adequately 
absorbed antisera, strains that agglutinate very strongly and equally with both the 
Ogawa and Inaba antisera are rarely, if  ever, encountered. If such reactions are 
suspected, the strains should be referred to a reference laboratory for further 
examination and may be referred to as “possible serotype Hikojima.”
Refer to Chapter 11 for a discussion on quality control o f antisera.
T ab le  6-2. S e ro ty p es  of V cholerae se rog rou p  O1
Agglutination in 
absorbed antiserum




3. Slide agglutination procedures
Agglutination tests for V. cholerae somatic O antigens may be carried out in a 
petri dish or on a clean glass slide. Use an inoculating loop or needle, sterile 
applicator stick, or toothpick to remove a portion o f the growth from the surface of  
HIA, KIA, TSI, or other nonselective agar medium. Emulsify the growth in two 
small drops of physiological saline and mix thoroughly. Add a small drop of  
antiserum to one o f the suspensions. Usually approximately equal volumes of  
antiserum and growth suspension are mixed, but the volume o f suspension may be 
as much as double the volume o f the antiserum. To conserve antiserum, volumes 
as small as 10 microliters (0.01 ml) can be used. An inoculating loop may be used 
to dispense small amounts o f antisera if  micropipettors are not available (Figure 
4-12). Mix the suspension and antiserum well and then tilt the slide back and 
forth to observe for agglutination. If the reaction is positive, clumping will appear 
within 30 seconds to 1 minute. Examine the saline suspension carefully to ensure 
that it does not show clumping due to autoagglutination. If autoagglutination 
occurs, the culture is termed “rough” and cannot be serotyped.
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4. Confirmation of V cholerae O139
A suspected V. cholerae isolate that reacts in O139 antiserum but not in 
polyvalent O1 antiserum should be sent to a reference laboratory. Confirmation 
o f V. cholerae O139 includes testing for production of cholera enterotoxin and 
verification o f the O139 antigen. No serotypes have been identified in the O139 
serogroup.
C. Media and Reagents for V. cholerae
1. Alkline peptone water
[Note: There are several different published formulations for this medium.]
Peptone 10.0 g
NaCl 10.0 g
Distilled water 1000.0 ml
Add ingredients to the water and adjust to pH 8.5 with 3 N  NaOH solution. 
Distribute and autoclave at 121°C for 15 minutes. Store at 4°C for up to 6 
months making sure caps are tightly closed to prevent a drop in pH or 
evaporation.
When inoculated into APW for quality control, V. cholerae O1 should show 
good growth at 6 to 8 hours.
2. Kligler iron agar and triple sugar iron agar
[Note: There are several commercially available dehydrated formulations of 
KIA and TSI. These media can also be prepared from individual ingredients but 
there may be lot-to-lot variation.]
Prepare according to manufacturer’s instructions. Dispense a quantity of  
medium in appropriate containers such that the volume o f medium is sufficient to 
give a deep butt and a long slant. For example, dispense 6.5 ml o f medium into 16 
x 125-mm screw-cap tubes (leave caps loose), and after autoclaving, allow the 
slants to solidify in a manner such that the medium in the butt o f the tube is 3 cm 
deep and the slant is 2 cm long. Tighten caps and store at 4°C for up to 6 months.
Each new lot should be quality controlled before use. E. coli should give an 
acid slant and butt, with production o f gas but no H2S. S. flexneri should give an 
alkaline slant, acid butt, without production o f gas or H2S [Note: some
5. flexn eri6 strains produce gas].
3. Lysine iron agar
[Note: Several companies sell dehydrated LIA. LIA may also be prepared from 
individual ingredients but there may be lot-to-lot variation.]
Prepare medium according to manufacturer’s instructions on the bottle. Dis­
pense a quantity o f medium in appropriate containers such that the volume of
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medium is sufficient to give a deep butt and a long slant. For example, dispense 
6.5 ml o f medium into 16 x 125-mm screw-cap tubes (leave caps loose), and after 
autoclaving, allow the slants to solidify in a manner such that the medium in the 
butt o f the tube is about 3 cm deep and the slant is about 2 cm long. When the 
agar is cooled and solidified, tighten caps and store at 4°C for up to 6 months.
Each new lot o f dehydrated medium should be quality controlled before use. S. 
flexneri should produce an alkaline slant and an acid butt without production o f 
H2S. H2S-producing Salm onella strains should produce an alkaline slant and an 
alkaline butt with blackening o f the medium due to H2S. V. cholerae strains are 
lysine-positive and will produce an alkaline reaction in the butt o f the LIA.
4. Oxidase reagent
-Tetramethyl-p-phenylenediamine dihydrochloride 0.05 g
Distilled water 5.0 ml
Dissolve the reagent in purified water (do not heat to dissolve). Prepare 
fresh daily.
Positive and negative controls should be tested every time the reagent is 
prepared. V. cholerae is oxidase positive; E. coli is oxidase negative.
5. Sodium deoxycholate reagent (0.5%) for string test
Sodium deoxycholate 0.5 g
Sterile distilled water 100.0 ml
Add sterile distilled water to sodium deoxycholate and mix well. Store at room 
temperature for up to 6 months.
Each new batch should be quality controlled before use. A V. cholerae O1 
strain should be used as positive control. E. coli may be used as a negative 
control.
6. Thiosulfate citrate bile salts sucrose agar
[Note: Several commercial brands o f thiosulfate citrate bile salts sucrose agar 
(TCBS) agar are available. This medium can also be prepared from individual 
ingredients, but results may be much more variable than with a commercial 
dehydrated formulation.]
Follow manufacturer’s instructions to weigh out and suspend the dehydrated 
medium. Heat with agitation. Medium should be completely dissolved. Cool 
agar in a water bath until cool enough to pour (50° to 55°C). Pour into petri 
plates, leaving lids ajar about 20 minutes so that the surface of the agar will dry. 
Close lids and store at 4°C for up to 1 week.
Each new lot should be quality controlled before use since TCBS is subject to 
lot-to-lot and brand-to-brand variations in selectivity. V. cholerae O1 should
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show good growth o f yellow colonies. E. coli should have none to poor growth 
of translucent colonies.
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Chapter 7 
Epidemiology of Escherichia coliSerotype O157:H7
Escherichia coli O157:H7 is a recently recognized pathogen that causes a 
dysentery-like illness. The disease is typically a bloody diarrhea, often without 
prominent fever, that can be complicated by hemolytic uremic syndrome. It is 
primarily found in developed countries. Only one confirmed outbreak has occurred 
in a developing country-in Swaziland in 1992 affecting 20,000 persons. Other 
outbreaks have been thought to occur but have not been confirmed.
The major modes o f transmission are through undercooked beef, unpasteurized 
milk, and foods that have come in contact with materials o f animal origin. Water­
borne outbreaks have been reported, as have outbreaks associated with swimming 
in contaminated lakes.
The organism produces toxins similar to those produced by Shigella dysenteriae 
serotype 1. Treatment with antimicrobial agents has not been demonstrated to be 
useful in improving the course or outcome o f infection with E. coli O157:H7. In 
fact, treating with some agents may actually worsen the outcome. Since no 
treatment is recommended, it is not necessary to test the antimicrobial susceptibil­
ity o f isolates of E. coli O157:H7.
Laboratories should be familiar with this organism and should periodically look 
for it in stools from patients with bloody diarrhea. It is not necessary to examine 
every stool submitted to the laboratory for E. coli O157:H7, but it should be 
considered in outbreaks o f dysentery in which Shigella  spp. are not isolated from 
the stools o f patients with bloody diarrhea. Laboratory supplies required for 
diagnosis o f E. coli O157:H7 are listed in Annex H.
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Chapter 8 
Isolation and Identification of Escherichia coli 
Serotype O157:H7
Isolation and identification o f Escherichia coli serotype O157:H7 can be 
greatly enhanced when optimal laboratory media and techniques are employed. 
The methods presented here are intended to be economical and to offer 
laboratorians some flexibility in choice of protocol and media. Laboratories that 
do not have sufficient resources to adopt the methods described below should 
consider sending specimens or isolates to other laboratory facilities that 
routinely perform these procedures. Laboratory supplies required for diagnosis of 
E. coli O157:H7 are listed in Annex H.
A. Isolation and Identification Methods
E. coli O157:H7 rapidly ferments lactose and is indistinguishable from most 
other E. coli serotypes on traditional lactose-containing media. However, unlike 
approximately 80% of other E. coli, nearly all isolates of E. coli O157:H7 
ferment D -sorbitol slowly, or not at all. Sorbitol-MacConkey (SMAC) agar was 
developed to take advantage o f this characteristic by substituting the carbohydrate 
sorbitol for lactose in MacConkey agar, and it is the medium o f choice for 
isolation o f E. coli O157:H7. Sorbitol-negative colonies will appear colorless on 
SMAC (Figure 8-1).
F ig u re  8-1. E. c o liO 157:H 7 co lon ies a re  co lo rless on SMAC. N on-O 157 E. coli 
co lon ies a re  pink.
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Enrichment for E. coli O157:H7 is not usually necessary for isolation o f the 
organism from acutely ill patients.
Figure 8-2 illustrates the procedure for recovery o f E. coli O157:H7 from fecal 
specimens. SMAC is inoculated as described in Chapter 4 (Figure 4-2). Incubate 
18 to 24 hours at 35° to 37°C. After 18 to 24 hours’ incubation, the amount and 
type o f growth (e.g., sorbitol-positive or sorbitol-negative) on SMAC should be 
recorded on data sheets for each patient specimen (Figure 8-3). Colonies suspicious 
o f E. coli O157:H7 will appear colorless and about 2 to 3 mm in diameter 
(Figure 8-1).
Test sorbitol-negative colonies selected from SMAC with E. coli O157 anti­
serum or latex reagents (O157 antibody-coated latex and control latex) according to 
the procedures recommended by the manufacturer. Suspected colonies may be 
tested with antisera directly from the SMAC plate or subcultured to a nonselective 
medium (HIA, for example) and tested the next day. This provides more growth 
on which to perform the agglutination assay (however, some manufacturers of 
O157 latex reagents recommend testing only colonies taken directly from the 
plate). If colonies are tested directly from the plate, a colony that is positive in 
O157 latex reagent should also be transferred to another medium for subsequent 
testing. Once one colony from a plate has been identified as O157-positive, no 
further colonies from the same plate need to be tested.
S p e c im e n
I
S M A C  
c o lo r le s s  c o lo n ie s
O p tio n a l: 
N o n s e le c t iv e  a g a r
I
O 1 5 7  S e ro lo g y  
+
I
R e f e r e n c e  L a b o ra to ry
F ig u re  8-2. P rocedu re  for recovery  of E. coli 
O 157:H 7 from fecal sp ec im en s
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If O157 latex reagent is used, it is important to test any positive colonies in 
the latex control reagent also; this is because some sorbitol-nonfermenting 
organisms will react nonspecifically with latex. The manufacturers o f these kits 
recommend that strains reacting in both the antigen-specific and control latex 
reagents be heated and retested. However, in a study that used this procedure, 
none o f the nonspecifically reacting strains were subsequently identified as 
E. coli O157:H7.
Isolates that are O157 positive should be sent to a reference laboratory for 
confirmation. The reference laboratory should identify isolates biochemically as 
E. coli because strains o f several species cross-react with O157 antiserum. 
Identification o f the H7 flagellar antigen is also required for confirmation.
Isolates that are nonmotile or that are negative for the H7 antigen should be tested 
for production o f Shiga toxins to identify pathogenic strains.
It is not necessary to test E. coli O157:H7 isolates for susceptibility to 
antimicrobial agents (see Chapter 7).
B. Preparation and Quality Control of Sorbitol-MacConkey agar
Prepare according to the manufacturer’s instructions. [Note: Several brands of 
SMAC are available commercially. This medium can also be prepared from 
individual ingredients, but results may be much more variable than with a com­
mercial dehydrated formulation.] Sterilize by autoclaving at 121°C for 15 
minutes. Cool to 50°C and pour into petri plates. Leave lids ajar for about 20 
minutes so that the surface o f the agar will dry. Close lids and store at 4°C for up 
to 1 month. If medium is to be stored for more than a few days, put plates in a 
sealed plastic bag to prevent drying. Each new lot should be quality controlled 
before use.
E. coli should produce good to excellent growth o f pink to red colonies.
E. co liO157:H7 should produce colorless colonies.
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Antimicrobial Susceptibility Testing (Agar Disk 
Diffusion Method)
The disk diffusion method presented in this chapter has been carefully stan­
dardized by the National Committee for Clinical Laboratory Standards (NCCLS) 
and if  performed precisely according to the protocol below, will provide data that 
can reliably predict the in vivo effectiveness o f the drug in question. However, 
any deviation from the method may invalidate the results. For this reason, if  
laboratories lack the resources to perform the disk diffusion test exactly as 
described, they should forward isolates to other laboratories for susceptibility 
testing.
A. Considerations for Antimicrobial Susceptibility Testing
As antimicrobial resistance increases in many parts o f the world, it becomes 
increasingly important to monitor the antimicrobial susceptibility o f Shigella and 
Vibrio cholerae O1 and O139. However, because antimicrobial therapy for 
Escherichia coli O157:H7 infection has not been demonstrated to be efficacious 
or safe, except for cases o f cystitis and pyelonephritis, determination o f the 
antimicrobial susceptibility pattern is usually not meaningful.
See Chapters 3 and 5 for a discussion o f appropriate antimicrobial agents for 
treatment o f dysentery and cholera. Testing Shigella, V. cholerae, and E. coli 
O157:H7 against certain drugs may yield misleading results when in vitro results 
do not correlate with in vivo activity. Shigella  spp., for instance, are usually 
susceptible to aminoglycosides (e.g., gentamicin, kanamycin) in the disk diffusion 
test, but treatment with these drugs is often not effective. Some special consider­
ations for susceptibility testing o f V cholerae are discussed in section B below. 
Antimicrobial agents suggested for use in susceptibility testing o f Shigella and V 
cholerae are listed in Table 9-1.
B. Procedure for Agar Disk Diffusion
Figure 9-1 summarizes the disk diffusion method of susceptibility testing. 
Laboratory supplies required for Shigella and V. cholerae disk diffusion testing 
are listed in Annexes A and B.
1. Mueller-Hinton susceptibility test agar
Mueller-Hinton agar medium is the only susceptibility test medium that has 
been validated by NCCLS. Mueller-Hinton agar should always be used for disk 
diffusion susceptibility testing, according to NCCLS and international guidelines. 
Because the way Mueller-Hinton is prepared can affect disk diffusion test results, 
it is very important to refer to Section C below for instructions on preparation and 
quality control of this medium.
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T ab le  9-1. Antimicrobial a g e n ts  su g g e s te d  for u se  in susceptib ility  testing  of Shigella 
an d  V cholerae O1 an d  O 139
a If re s is tan t to nalidixic acid, te s t  with ciprofloxacin. 
b T he resu lts  from th e  te tracycline disk a re  u sed  to predict susceptib ility  to 
doxycycline also.
2. McFarland turbidity standard
A McFarland 0.5 standard should be prepared and quality controlled prior to 
beginning susceptibility testing (see Section C). If tightly sealed to prevent 
evaporation and stored in the dark, the standard can be stored for up to 6 months. 
The McFarland standard is used to adjust the turbidity o f the inoculum for the 
susceptibility test.
3. Preparation of inoculum
Each culture to be tested should be streaked onto a noninhibitory agar medium 
(blood agar, brain heart infusion agar, or tryptone soy agar) to obtain isolated 
colonies. After incubation at 35°C overnight, select 4 or 5 well-isolated colonies 
with an inoculating needle or loop, and transfer the growth to a tube o f sterile 
saline (see Section C) or nonselective broth (Mueller-Hinton broth, heart infusion 
broth, or tryptone soy broth) and vortex thoroughly. The bacterial suspension 
should then be compared to the 0.5 McFarland standard. This comparison can be 
made more easily i f  the tubes are viewed against a sheet o f white paper on which 
sharp black lines are drawn (see Figures 9-2 and 9-3). The turbidity standard 
should be agitated on a vortex mixer immediately prior to use. If the bacterial 
suspension does not appear to be the same density as the McFarland 0.5, the 
turbidity can be reduced by adding sterile saline or broth or increased by adding 
more bacterial growth.
Alternatively, the growth method may be used to prepare the inoculum.
Four or five colonies are picked from overnight growth on agar and inoculated 
into broth (Mueller-Hinton broth, heart infusion broth, or tryptone soy broth). 
Incubate the broth at 35°C until turbid, and then adjust the turbidity to the 
proper density.
























F ig u re  9-1. Procedure for disk 
diffusion antimicrobial susceptibil­
ity testing
1 16-18 hr, 35°C
Measure zone sizes; 
interpret
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F ig u re  9-2. B ackground lines for viewing turbidity of inoculum
F ig u re  9-3. C om parison of M cFarland 0.5 with inoculum suspensio n . From  left to right, 
the  tu b es  are  the  M cFarland 0.5 standard , E. co liATCC 25922 ad justed  to th e  0.5 
M cFarland turbidity, and uninoculated saline.
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4. Inoculation procedure
Within 15 minutes after adjusting the turbidity o f the inoculum suspension, 
dip a sterile cotton swab into the suspension. Pressing firmly against the inside 
wall of the tube just above the fluid level, rotate the swab to remove excess 
liquid. Streak the swab over the entire surface o f the medium three times, 
rotating the plate approximately 60 degrees after each application to ensure an 
even distribution o f the inoculum (Figure 9-4). Finally, swab all around the edge 
o f the agar surface.
F ig u re  9-4. The Mueller-Hinton plate should be swabbed over the entire surface of 
the medium three times, rotating the plate 60 degrees after each application.
5. Antimicrobial disks
The working supply o f antimicrobial disks should be stored in the refrigerator 
(4°C). Upon removal o f the disks from the refrigerator, the package containing 
the cartridges should be left unopened at room temperature for approximately 1 
hour to allow the temperature to equilibrate. This reduces the amount o f conden­
sation on the disks. If a disk-dispensing apparatus is used, it should have a tight- 
fitting cover, be stored in the refrigerator, and be allowed to warm to room 
temperature before using.
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T ab le  9-2. Z one s ize  interpretative s ta n d a rd s  for Enterobacteriaceae for se le c te d  antim icrobial disks
D isk Z o n e  d ia m e te r  (m m ) Z o n e  d ia m e te r  lim its  (m m )
A n tim ic ro b ia l
ag en t
p o ten cy
(Mg) R es is tan t In te rm ed ia te S u sce p tib le
fo r
E. c o li A T C C  2 59 2 2
C h lo ram p h en ic o lab 30 < 1 2 13-17 > 1 8 21 -2 7
A m p ic illin “ 10 <13 14-16 > 1 7 16-22
F u raz o lid o n e0 
fo r  V. cholerae
100 <18 - > 1 8 22 -26
T  r im e th o p rim - 
su lfam e th o x az o le“
1.25 /
2 3 .7 5 < 1 0 11-15 > 1 6 24 -3 2
T e tracy c lin e“ 3 0 < 1 4 15-18 > 1 9 18-25
C ip ro flo x ac in “-d 5 <15 16-20 >21 30 -4 0
N a lid ix ic  ac id“ 3 0 <13 14-18 > 1 9 2 2 -2 8
N a lid ix ic  ac id 0 
fo r  V. cholerae
30 <1 9 - > 1 9
aSource: National Committee on Clinical Laboratory Stan dards (NCCLS), 1998.
bU se these interpretive standards with caution a s  the disk diffusion test may misclassify many organism s (high minor error rate) 
cProposed interpretive criteria based  on multi-laboratory studies. Criteria have not been established for V. cholerae  by NCCLS.
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Apply the antimicrobial disks to the plates as soon as possible, but no longer 
than 15 minutes after inoculation. Place the disks individually with sterile forceps 
or with a mechanical dispensing apparatus, and then gently press down onto the 
agar. In general, place no more than 12 disks on a 150-mm plate and no more 
than 4 disks on a 100-mm plate. This prevents overlapping of the zones of  
inhibition and possible error in measurement. Diffusion of the drug in the disk 
begins immediately; therefore, once a disk contacts the agar surface, the disk 
should not be moved.
6. Recording and interpreting results
After the disks are placed on the plate, invert the plate and incubate at 35°C for 
16 to 18 hours. After incubation, measure the diameter o f the zones o f complete 
inhibition (including the diameter o f the disk) (Figure 9-5) and record it in 
millimeters (Figures 9-6, 9-7). The measurements can be made with a ruler on the 
undersurface o f the plate without opening the lid. With sulfonamides and 
trimethoprim-sulfamethoxazole, a slight amount of growth may occur within the 
inhibition zone. In this instance, slight growth (80% inhibition) should be ignored 
and the zone diameter should be measured to the margin o f heavy growth. The 
zones o f growth inhibition should be compared with the zone-size interpretative 
table (see Table 9-2), and recorded as susceptible, intermediate, or resistant to 
each drug tested.
Colonies growing within the clear zone o f inhibition may represent resistant 
variants or a mixed inoculum. The distance from the colony(ies) closest to the 
disk to the center of the disk should be measured and then doubled to obtain a 
diameter. The diameter o f the outer clear zone should be recorded as well and an 
interpretation recorded for each diameter. The colony(ies) inside the zone should 
be picked, re-isolated, re-identified, and retested in the disk diffusion test to 
confirm the previous results. The presence o f colonies within a zone o f inhibition 
may predict eventual resistance to that agent.
7. Quality control
To verify that susceptibility test results are accurate, it is important to include 
at least one control organism (ATCC 25922 is the E. coli control strain used when 
testing Enterobacteriaceae and V cholerae) with each test. Zone diameters 
obtained for ATCC 25922 should be compared with NCCLS published limits (see 
Table 9-2 for diameters o f the zones o f inhibition for ATCC 25922). If zones 
produced by the control strain are out o f the expected ranges, the laboratorian 
should consider possible sources o f error.
Susceptibility tests are affected by variations in media, inoculum size, incuba­
tion time, temperature, and other factors. The medium used may be a source o f 
error if  it fails to conform to NCCLS recommended guidelines. For example, agar 
containing excessive amounts o f thymidine or thymine can reverse the inhibitory 
effects o f sulfonamides and trimethoprim, causing the zones of growth inhibition 
to be smaller or less distinct. Organisms may appear to be resistant to these drugs
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F ig u re  9-5. R esu lts of th e  disk diffusion assay . This Shigella iso late is 
re s is tan t to trim ethoprim -su lfam ethoxazo le and  is growing up to  the  
disk (SXT), th e  zo n e  of which is reco rded  a s  6 mm.
when in fact they are not. If the depth o f the agar in the plate is not 3 to 4 mm or 
the pH is not between 7.2 and 7.4, the rate o f diffusion o f the antimicrobial agents 
or the activity o f the drugs may be affected.
If the inoculum is not a pure culture or does not contain a concentration o f  
bacteria that approximates the McFarland standard, the susceptibility test results 
will be affected. For instance, a resistant organism could appear to be susceptible 
if  the inoculum is too light. Also, if  colonies from blood agar medium are used to 
prepare a suspension by the direct inoculum method, trimethoprim or sulfonamide 
antagonists may be carried over and produce a haze o f growth inside the zones of  
inhibition surrounding trimethoprim-sulfamethoxazole disks even when testing 
susceptible isolates.
If antimicrobial disks are not stored properly or are used beyond the stated 
expiration date, their potency may decrease; this will usually be indicated by a 
decrease in the size o f the inhibition zone around the control strain.
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F ig u re  9-6. S am p le  w o rk sh ee t for recording disk diffusion susceptib ility  resu lts  for V. 
cholerae O1 or O 139
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F ig u re  9-7. S am p le  w o rk sh ee t for recording disk diffusion susceptib ility  resu lts for 
Shigella iso lates
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As mentioned above, testing some bacteria against certain antimicrobial 
agents may yield misleading results because these in vitro results do not neces­
sarily correlate with in vivo activity. Examples include narrow- and expanded- 
spectrum cephalosporins and aminoglycosides (e.g., gentamicin) tested against 
Shigella spp. (see Chapter 3), and erythromycin tested against V. cholerae (see 
section C below).
C. Special Considerations for Susceptibility Testing of V. cholerae
Although the disk diffusion technique is the most commonly used method for 
antimicrobial susceptibility testing, zone size interpretive criteria for V cholerae 
O1 and O139 have been established only for ampicillin, chloramphenicol, 
sulfonamides, tetracycline and trimethoprim-sulfamethoxazole. It has been 
determined that disk diffusion results are not accurate for V. cholerae when testing 
erythromycin and doxycycline, and these agents should not be tested by this 
method. The results from the tetracycline disk should be used to predict suscepti­
bility to doxycycline. If susceptible to tetracycline, the strain will be susceptible 
to doxycycline. At this time there is no in vitro method to accurately determine 
susceptibility to erythromycin.
The reliability o f disk diffusion results for other antimicrobial agents, including 
ciprofloxacin, furazolidone and nalidixic acid, has not been validated. Until 
interpretive criteria have been established for V. cholerae, disk diffusion may be 
used to screen for resistance to ciprofloxacin, using interpretive criteria for the 
Enterobacteriaceae as tentative zone size standards. Tentative breakpoints have 
been proposed for testing furazolidone and nalidixic acid with V. cholerae (see 
Table 9-2). When screening with the disk diffusion method for these agents, 
results should be interpreted with caution. If zone sizes for these drugs fall within 
the intermediate range, the organism should be considered possibly resistant.
D. Preparation and Quality Control of Media and Reagents
1. Mueller-Hinton agar
[Note: Several commercial formulations o f Mueller-Hinton agar are available. 
This medium should not be prepared from individual ingredients because this can 
diminish the quality. Commercial dehydrated Mueller-Hinton is carefully quality 
controlled before being released for sale.]
Follow manufacturer’s instructions to prepare medium. After autoclaving, cool 
medium to 50°C. Measure 60 to 70 ml o f medium per plate into 15 x 150-mm 
plates, or measure 25 to 30 ml per plate into 15 x 100-mm plates. Agar should be 
poured into flat-bottom glass or plastic petri dishes on a level pouring surface to a 
uniform depth o f 4 mm. Using more or less agar will affect the susceptibility 
results. Agar deeper than 4 mm may cause false-resistance results, whereas agar 
less than 4 mm deep may be associated with a false-susceptibility report.
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Freshly prepared plates may be used the same day or stored in a refrigerator 
(2° to 8°C) for up to 2 weeks. If plates are not used within 7 days o f preparation, 
they should be wrapped in plastic to minimize evaporation. Just before use, if  
excess moisture is on the surface, plates should be placed in an incubator (35° to 
37°C ) until the moisture evaporates (usually 10 to 30 min). Do not leave lids 
ajar because the medium is easily contaminated.
Each new lot should be quality controlled before use by testing the E. coli 
ATCC 25922 and/or Staphylococcus aureus ATCC 25923 standard strains. 
These standard strains are used with every test run for Enterobacteriaceae and 
gram-positive aerobes, respectively. The pH o f each new lot o f Mueller-Hinton 
should be between 7.2 to 7.4. If outside this range, the pH medium should not be 
adjusted by the addition o f acid or base; the batch o f plates should be discarded 
and a new batch o f plates prepared. If the pH for every batch is too high or low, 
the entire lot o f dehydrated medium may have to be returned to the manufacturer 
as unsatisfactory.
2. Turbidity standards (McFarland)
McFarland 0.5 turbidity standards are available from various manufacturers. 
Alternately, the 0.5 McFarland may be prepared by adding 0.5 ml o f a 1.175% 
(wt/vol) barium chloride dihydrate (BaCl2̂ 2H2O) solution to 99.5 ml o f 1% (vol/ 
vol) sulfuric acid. The turbidity standard is then aliquoted into test tubes identical 
to those used to prepare the inoculum suspension. Seal the McFarland standard 
tubes with wax, Parafilm, or some other means to prevent evaporation. McFarland 
standards may be stored for up to 6 months in the dark at room temperature (22° 
to 25°C). Discard after 6 months or sooner if  any volume is lost. Before each use, 
shake well, mixing the fine white precipitate o f barium sulfate in the tube.
The accuracy o f the density o f a prepared McFarland standard should be 
checked by using a spectrophotometer with a 1-cm light path; for the 0.5 
McFarland standard, the absorbance at a wavelength of 625 nm should be 0.08 to 
0.1. Alternately, the accuracy o f the McFarland standard may be verified by 
adjusting a suspension o f a control strain (e.g., E. coli ATCC 25922) to the same 
turbidity, preparing serial 10-fold dilutions, and then performing plate counts (see 




Distilled water 1 liter
Dissolve NaCl in water, heating if  necessary. May be sterilized by autoclaving 
or membrane filtration. Store at ambient temperature for up to 6 months with caps 
tightened to prevent evaporation.
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1% sulfuric acid 
(v/v)
















F ig u re  9-8. P ro ced u re  for p reparation  and quality control of th e  M cFarland 0.5 
s ta n d a rd
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Shigella, Vibrio cholerae, or Escherichia coli serotype O157:H7 will usually 
remain viable for several days on solid medium held at ambient temperature (22° 
to 25°C) unless the medium dries out or becomes acidic. However, if  cultures are 
to be maintained for longer than a few days, they should be appropriately pre­
pared for storage. Selection o f a storage method depends on the length o f time the 
organisms are to be held and the laboratory equipment and facilities available.
A. Short-term Storage
Blood agar base (BAB), tryptone soy agar (TSA), and heart infusion agar 
(HIA) are examples of good storage media for enteric organisms. Carbohydrate- 
containing media (e.g., Kligler iron agar or triple sugar iron agar) should not be 
used because acidic byproducts o f metabolism quickly reduce viability. BAB, 
TSA, and HIA all contain salt, which enhances growth o f V. cholerae. Nutrient 
agar should not be used for growth or storage o f V. cholerae since it has no added 
salt.
When preparing storage medium, while the tubes are still hot after autoclaving, 
place them in a slanted position to provide a short slant and deep butt (2 to 3 cm). 
To inoculate, stab the inoculating needle to the butt o f the medium once or twice, 
then streak the slant. Incubate overnight at 35° to 37°C. Seal the tube with cork 
stoppers that have been soaked in hot paraffin or treated in some other way to 
provide a tight seal. Store cultures at 22° to 25°C in the dark.
Sterile mineral oil may also be used to prevent drying o f slants. Add sufficient 
sterile mineral oil to cover the slants to 1 cm above the top o f the agar. Subcul­
ture when needed by scraping growth from the slant; there is no need to remove 
mineral oil to subculture. Strains maintained in pure culture in this manner will 
usually survive for several years.
B. Long-term Storage
Bacterial cultures may be stored frozen or lyophilized in a variety o f suspend­
ing media formulated for that purpose. There are many formulations o f  
suspending medium, but in general, skim milk, serum-based media, or polyvi­
nylpyrrolidone (PVP) medium is used for lyophilization, and skim milk, blood, or 
a rich buffered broth such as tryptone soy broth with 15% to 20% reagent grade 
glycerol is used for freezing.
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Frozen storage (ultralow freezer, -70°C; or liquid nitrogen 
freezer, -196°C)
Isolates may be stored indefinitely if  they are maintained frozen at -70°C or 
below. Storage at -20°C is not recommended because some organisms will lose 
viability at this temperature.
• Inoculate a TSA or HIA slant (or other noninhibitory, salt-containing growth 
medium) and incubate overnight at 35° to 37°C.
• Harvest cells from the slant and make a suspension in freezing medium.
• Dispense suspension into cryovials (freezing vials specially designed for use 
at very low temperatures). Caution: Do not use glass ampoules for freezing 
in liquid nitrogen because they can explode upon removal from the freezer.
• Prepare an alcohol and dry ice bath by placing dry ice (frozen CO2) in a 
leakproof metal container large enough to hold a metal culture rack, and add 
enough ethyl alcohol to submerge about half o f the cryovial. Rapidly freeze 
the suspension by placing the sealed vials in the dry ice bath until frozen. 
Transfer the frozen vials to a freezer. If there is no dry ice available, a 
container o f alcohol may be placed in the freezer overnight and then used to 
quick-freeze vials.
R ecovery o f  cultures fro m  frozen  storage
• Place frozen cultures from the freezer on dry ice or into an alcohol and dry ice 
bath and transfer to a laboratory safety cabinet or to a clean area if  a cabinet 
is not available.
• Using a sterile loop, scrape the topmost portion o f the culture and transfer to 
growth medium, being careful not to contaminate the top or inside o f
the vial.
• Reclose vial before the contents completely thaw, and return vial to the 
freezer. With careful technique, transfers can be successfully made from the 
same vial several times.
Lyophilization
Most organisms may be successfully stored after lyophilization (freeze-drying). 
Freeze-drying involves the removal o f water from frozen bacterial suspensions by 




Quality Control of Media and Reagents
Each laboratory must ensure adequate control o f the media and reagents it uses. 
Quality control includes the selection o f satisfactory raw materials, the prepara­
tion o f media according to approved formulations or specific manufacturer’s 
instructions, and the use o f well-characterized reference strains to check prepared 
media.
A. Quality Control of Media
1. Considerations for quality control of media
Each batch o f medium prepared from individual ingredients or each different 
manufacturer’s lot number o f dehydrated medium should be tested for one or more 
of the following characteristics, as appropriate:
• Sterility
• Ability to support growth o f the target pathogen(s)
• Ability to produce appropriate biochemical reactions
S terility
One tube or plate from each autoclaved or filter-sterilized batch o f medium 
should be incubated overnight at 35° to 37°C and examined for contaminants.
A b ility  to support grow th o fth e  target organism (s)
• For selective media: use at least one strain to test for ability to support 
growth o f the target pathogen (e.g., for MacConkey agar (MAC), a Shigella 
strain such as S. ilexneri); it should also be noted if  this strain produces the 
appropriate biochemical reactions/color on the test medium (see below).
A b ility  to produce appropriate biochem ical reactions
• For selective media: use at least one pathogen and one nonpathogen to test 
for the medium’s ability to differentiate target organisms from competitors 
(e.g., for MAC, a lactose-nonfermenting organism such as S. ilexneri and a 
lactose-fermenting organism such as E. coli).
• For biochemical media: use at least one organism that will produce a 
positive reaction and at least one organism that will produce a negative 
reaction (e.g., for urea medium, a urease-positive organism such as Proteus 
and a urease-negative organism such as E. coli).
2. Methods for quality control of media
When testing for ability to support growth, to avoid using too heavy an inocu­
lum, prepare a dilute suspension to inoculate the medium. A small inoculum will
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give greater assurance that the medium is adequate for recovery o f a small number 
o f organisms from a clinical specimen. An example o f a protocol for quality 
control o f media is given here:
• The control strain is inoculated to nonselective broth (e.g., tryptone soy 
broth) and grown up overnight.
• To prepare a standardized inoculum for testing selective and inhibitory 
media, make a 1:10 dilution o f the overnight nonselective broth culture.
If testing nonselective media, prepare an additional 1:10 dilution (to give a 
1:100 dilution o f the broth).
• One tube or plate o f each medium should be inoculated with the standardized 
inoculum o f the control strain(s). When testing selective plating media, a 
nonselective plating medium such as heart infusion agar should be inoculated 
at the same time for comparison purposes.
• Using a loopful o f the 1:10 or 1:100 dilution prepared above (use a calibrated 
loop, if  available) inoculate media to be tested, streaking for isolation on 
plating media. The same loop should be used for all quality control o f all 
media; it is more important to use the same inoculating loop every time than 
it is to use a calibrated loop.
3. Sources of quality control strains
Suitable quality control strains may be obtained in several different ways.
A laboratory may use strains isolated from clinical specimens or quality assurance 
specimens, provided the strains have been well characterized by all available 
methods (e.g., biochemical, morphologic, serologic, molecular). Many laborato­
ries purchase quality control strains from official culture collections, such as the 
National Collection o f Type Cultures (Public Health Laboratory Service, London 
NW9, England) or the American Type Culture Collection (12301 Parklawn Drive, 
Rockville, MD 20852). Quality control strains also may be purchased from 
commercial companies such as Lab M (Topley House, 52 Wash Lane, Bury, BL9 
6AU, England).
B. Quality Control of Reagents
As with all other products used in testing, reagents, either purchased or pre­
pared in the laboratory, should be clearly marked to indicate the date on which 
they were first opened and the expiration date, if  appropriate. Each reagent 
should be tested to make sure the expected reactions are obtained. If the reagent 
is a rare, expensive, or difficult-to-obtain product such as diagnostic antiserum, it 
does not necessarily have to be discarded on the expiration date. If satisfactory 
sensitivity and specificity can still be verified by normal quality control procedures, 
the laboratory may indicate on the vial label the date o f verification o f quality of the 
reagent. All reagents should be tested for quality at intervals established by each 
laboratory to ensure that no deterioration has occurred.
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For quality control o f antiserum, two or more control strains (one positive and 
one negative) should be used to test its agglutination characteristics. The results 
of all reactions should be recorded. Following is an example o f a typical quality 
control procedure.
• Place a drop (about 0.05 ml) of each antiserum on a slide or plate. Also, 
place a drop o f 0.85% saline on each slide or plate to test each antigen for 
roughness or autoagglutination.
• Prepare a densely turbid suspension (McFarland 2 or 3; see Table 11-1) of  
each control isolate in normal saline with growth aseptically harvested from 
an 18- to 24-hour culture from nonselective agar (for example, heart infusion 
agar or tryptone soy agar).
• Add one drop o f the antigen suspension to the antiserum and the saline. Mix 
thoroughly with an applicator stick, glass rod, or inoculating loop. Rock the 
slide back and forth for 1 minute.
• Read the agglutination reaction over a light box or an indirect light source 
with a dark background. The saline control must be negative for agglutina­
tion for the test to be valid.
The degree o f agglutination should be read and recorded as follows:
Percent agglutination Record reaction as:
S lid e  a g g lu tin a tio n  m e th o d  fo r  q u a lity  co n tro l o fa n tis e ra
C. Advantages of Centralized Acquisition of Media and Reagents
There are several benefits o f centralizing acquisition o f media and reagents in 
the national reference laboratory or Ministry o f Health:
• Large amounts o f a single lot o f medium or reagent can be purchased and 
subsequently divided into smaller aliquots for distribution to provincial/ 
district laboratories. This may be more cost effective (i.e., discount for larger 
orders, lower shipping costs, less waste because o f product going past 
expiration date).
• Quality control can be performed in the central laboratory, avoiding duplica­
tion o f effort among provincial and district laboratories. An unsatisfactory 
medium or reagent may then be returned to the manufacturer before the lot is 
distributed to other laboratories.
• The standardization o f methods among laboratories at all levels is facilitated 











Quality Control o f Media and Reagents
T ab le  11-1. Composition of McFarland turbidity standards
Turbidity 
standard  no.
B arium  chloride 
d ihydrate (1.175 %)
Sulfuric acid 
(1% )
C orresponding approxim ate 
density o f  bacteria/m l
0.5 0.5 m l 99.5 m l 1 x 108
1 0.1 m l 9.9 m l 3 x 108
2 0.2 m l 9.8 m l 6 x lO 8
3 0.3 m l 9.7 m l 9 x 10s
4 0.4 m l 9.6 m l 12 x lO 8
5 0.5 m l 9.5 m l 15 x 10s
6 0.6 m l 9.4 m l 18 x 108
7 0.7 m l 9.3 m l 21 x 108
8 0.8 m l 9.2 m l 24 x lO 8
9 0.9 ml 9.1 m l 27 x 10s
10 1.0 m l 9.0 m l 30 x lO 8
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Chapter 12 
Standard Safety Practices in the 
Microbiology Laboratory
Laboratorians working with infectious agents are subject to laboratory- 
acquired infections through accidents or unrecognized incidents. The degree of 
hazard depends upon the virulence o f the biological agent concerned and host 
resistance. Laboratory-acquired infections occur when microorganisms are 
inadvertently ingested, inhaled, or introduced into the tissues. The primary 
laboratory hazard associated with enteric pathogens such as Shigella  and 
E. coli O157:H7 is accidental ingestion. Biosafety Level 2 (BSL-2) practices 
are suitable for work involving these agents, which are a moderate potential 
hazard to personnel and the environment. BSL-2 requirements:
• Laboratory personnel have specific training in handling pathogenic agents 
and are directed by competent scientists;
• Access to the laboratory is limited when work is being conducted;
• Extreme precautions are taken with contaminated sharp items;
• Certain procedures in which infectious aerosols or splashes may be created 
are conducted using protective clothing and equipment.
A. Standard Microbiological Safety Practices
The safety guidelines listed below apply to all microbiology laboratories 
regardless o f biosafety level.
L im itin g  access to laboratory
Biohazard signs or stickers should be posted near all laboratory doors and on 
all equipment (incubators, hoods, refrigerators, freezers) used for laboratory 
work. Children under 12 years o f age and pets are not allowed in laboratory 
areas. All laboratories should be locked when not in use. All freezers and 
refrigerators located in corridors should be locked.
H andw ashing
Each laboratory should contain a sink for handwashing. Frequent 
handwashing is one o f the most effective procedures for avoiding laboratory- 
acquired infections. Hands should be washed with an appropriate germicidal 
soap before exiting the laboratory or after handling infectious materials.
E ating
Eating, drinking, and smoking are not permitted in the work areas. Food must 
be stored and eaten outside o f the work area in designated areas used for that 
purpose only. Do not lay personal articles such as handbags or eyeglasses on the 
workstations.
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M outh p ipettin g
Mouth pipetting should be strictly prohibited in the laboratory. Rubber bulbs 
or mechanical devices should be used.
Sharps
A high degree o f precaution must always be taken with any contaminated sharp 
items, including needles and syringes, slides, pipettes, capillary tubes, and 
scalpels. Dispose o f sharps in designated containers. To minimize finger sticks, 
used disposable needles must not be bent, sheared, broken, recapped, removed 
from disposable syringes, or otherwise manipulated by hand before disposal. 
Nondisposable sharps, including syringes, should be placed in a labeled discard 
pan for decontamination before cleaning. Broken glassware should not be 
handled directly by hand but should be removed by mechanical means such as a 
brush and dustpan, tongs, or forceps.
A erosols
Perform all procedures carefully to minimize the creation o f splashes or 
aerosols. Techniques that tend to produce aerosols should be avoided. Cool 
inoculating wires and loops by holding them still in the air for 5 to 10 seconds 
before touching colonies or clinical material. Loops containing infectious material 
should be dried in the hot air above the burner before flaming. Vortexing and 
centrifugation should be done in closed containers. Gauze should be used to 
remove the tops on blood specimens and should be placed around the top o f blood 
culture bottles to minimize aerosol production during removal o f the needle. 
Needles should never be cut or removed from the syringe before autoclaving. All 
body fluids should be centrifuged in carriers with safety caps only.
When procedures with a high potential for creating infectious aerosols are 
conducted or when there is a risk o f splashing or spraying the face with infectious 
or other hazardous materials, laboratory work should be conducted in a safety 
cabinet or with face protection (goggles, mask, face shield or other splatter 
guards). Procedures that pose a risk may include centrifuging, grinding, blending, 
vigorous shaking or mixing, sonic disruption, opening containers o f infectious 
materials whose internal pressures may be different from ambient pressures, 
inoculating animals intranasally, and harvesting infected tissues from animals or 
eggs. Face protection should also be used when working with high concentrations 
or large volumes o f infectious agents.
D econtam inating bench tops and  o ther surfaces
Bench tops should be wiped with a disinfectant (a phenolic disinfectant, 1% 
sodium hypochlorite, or 70% alcohol) routinely after working with infectious 
agents or clinical specimens or after spills, splashes, or other contamination by 
infectious materials. Solutions o f disinfectants should be maintained at the work 
station (see D isinfectants below).
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D isposal o f  contam inated m aterials
All discarded plates, tubes, clinical samples or other contaminated materials 
are to be placed in disposal containers at each bench. Special disposal boxes must 
be used for sharps such as syringes or broken glass to minimize the risk o f injury. 
Avoid overfilling such containers. Containers o f contaminated material should be 
carefully transported to the autoclave room and autoclaved before disposal.
A utoclaving
An autoclave must be available for the BSL-2/3 laboratory and must be 
operated only by personnel who have been properly trained in its use. To verify 
that each autoclave is working properly, spore strips or other biological indicators 
designed to test for efficiency o f sterilization should be included in autoclave 
loads on a regular basis. Each autoclave load should be monitored with tempera­
ture-sensitive tape, thermograph, or other means (e.g., biological indicators).
G eneral laboratory po licies
All areas o f the laboratory must be kept clean and orderly. Dirt, dust, crowd­
ing, or clutter is a safety hazard and is not consistent with acceptable biological 
research. Floors should be kept clean and free o f unnecessary clutter. They 
should be washed with a germicidal solution on a regular basis and after any spills 
o f infectious material have occurred.
R efrigerators and  freezers
Refrigerators and freezers should be regularly inspected for the presence of 
broken vials or tubes containing infectious agents. Wear gloves and proper attire 
when removing and discarding broken material. Refrigerators and freezers should 
be regularly cleaned with a disinfectant and defrosted to prevent possible contami­
nation and temperature failure.
F ire prevention
Keep burners away from lamps and flammable materials. Bulk flammable 
material must be stored in the safety cabinet. Small amounts o f these materials, 
such as ethyl acetate, ethyl alcohol, and methanol, can be stored in safety contain­
ers. Turn off burners when not in use. Know the location o f fire extinguishers, 
fire blankets, and showers. Fire safety instructions and evacuation routes should 
be posted.
B. Special Practices
T ransport o f  biohazardous m aterials
Transport o f biohazardous materials from one building to another increases the 
risk o f breakage and spills. If transport is necessary, the primary infectious agent 
container (regardless of size) must be placed in an unbreakable second container 
that can be sealed (e.g., screw-top tube, plastic bag).
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D isinfectants
Organisms may have different susceptibilities to various disinfectants. As a 
surface disinfectant, 70% alcohol is generally effective for the Enterobacteri- 
aceae, but other organisms are more resistant. However, 70% alcohol is not the 
disinfectant o f choice for decontaminating spills. Phenolic disinfectants, although 
expensive, are usually effective against many organisms. Always read disinfectant 
labels for manufacturers’ recommendations for dilution and for exposure times for 
efficacy, especially before use on BSL-3 organisms such as M ycobacterium  
tuberculosis. A good general disinfectant is a 1:100 (1%) dilution o f household 
bleach in water; at this dilution, bleach can be used for wiping surfaces of 
benches, hoods and other equipment. A 1:10 (10%) dilution o f bleach is corro­
sive and will pit stainless steel and should not be used routinely; however, it may 
be used to clean up spills o f cultured or concentrated infectious material where 
heavy contamination has occurred. Dilutions of sodium hypochlorite should be 
made daily from a stock solution.
D econtam ination o f  spills
The following procedure is recommended for decontaminating spills. Isolate 
the area to prevent anyone from entering. Wear gloves and protective clothing 
(gown or lab coat; mask if  the spill may contain a respiratory agent or if  the agent 
is unknown). Absorb or cover the spill with disposable towels. Saturate the 
towels with an appropriately diluted intermediate or high level disinfectant (e.g., a 
phenolic formulation or household bleach). Place disinfectant-soaked towels over 
the area and leave them in place for at least 15 minutes before removing and 
discarding them. Wipe area using clean disinfectant-soaked towels and allow area 
to air dry. Place all disposable materials used to decontaminate the spill into a 
biohazard container. Handle the material in the same manner as other infectious 
waste.
A ccidents
All injuries or unusual incidents should be reported immediately to the supervi­
sor. When cuts or puncture wounds from potentially infected needles or glassware 
occur, the affected area should be promptly washed with disinfectant soap and 
water. In the event o f a centrifuge accident in which safety carriers have not been 
used, other personnel in the area should be warned immediately and the area 
isolated to prevent anyone from entering.
C. Protective Clothing and Equipment
Laboratory coats
Protective coats, gowns, smocks, or uniforms designated for laboratory use 
must be worn while working in the laboratory. This protective clothing should be 
removed and left in the laboratory before leaving for non-laboratory areas. All 
protective clothing is either disposed o f in the laboratory or laundered by the 
institution; it should never be taken home by personnel.
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G loves
Regardless o f the type of infectious material, gloves should be worn when 
performing potentially hazardous procedures (e.g., slide agglutination) in which 
there is a risk o f splashing or skin contamination or when the laboratory worker 
has cuts or broken skin on his or her hands. Gloves should always be worn when 
handling clinical specimens, body fluids, and tissues from humans and animals. 
These tissues should be assumed to be positive for hepatitis B virus, HIV, other 
bloodborne pathogens, or M ycobacterium  tuberculosis. Gloves must be removed 
when contaminated by splashing or spills or when work with infectious materials 
is completed. Gloves should not be worn outside the laboratory. Do not use the 
telephone or open doors with gloves that have been used in laboratory procedures. 
Dispose o f all used gloves by discarding them with other disposable materials and 
autoclaving. Hands should be washed immediately after removing gloves.
B arrier precautions
Clinical specimens, body fluids, and tissues from humans and animals should 
be assumed to be positive for hepatitis B virus, HIV, other bloodborne pathogens, 
or M ycobacterium  tuberculosis. These materials should be handled in a safety 
cabinet or using other barrier precautions such as goggles, mask, face shield or 
other splatter guards whenever there is a potential for creating an aerosol.
References
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Packing and Shipping of Clinical Specimens and 
Etiologic Agents
A. Preparation for Transport of Infectious Specimens and Cultures
Transport o f clinical specimens and etiologic agents should be done with care 
to minimize the hazard to humans or the environment and also to protect the 
viability o f suspected pathogens. Transport o f infectious items by public or 
commercial delivery systems may be subject to local or national regulations.
If possible, send specimens so that they will arrive during working hours to 
ensure proper handling and prompt plating o f the specimens. Inform the receiving 
laboratory as soon as possible that the specimens are coming, preferably before 
sending the specimens.
Depending on local conditions, within-country transport may be by ground or 
by air. If specimens are sent by a messenger, the messenger must know the 
location o f the laboratory and the appropriate person to contact. The sender 
should identify the fastest and most reliable way o f transport in advance, whether 
it be by bicycle, motorcycle, car, ambulance or public transport, and should make 
sure that adequate funds are available to reimburse costs for fuel or public 
transport. For longer distances, the fastest transport service may be air freight or 
expedited delivery service. Since the ice packs or dry ice will last only 24 to 48 
hours, arrangements should be made for immediate collection at the receiving 
airport. When the specimens are shipped by air, the following information should 
be communicated immediately to the receiving laboratory: the air bill number, 
the flight number, and the times and dates o f departure and arrival o f the flight.
B. Transport and Shipment of Cultures and Specimens
1. Regulatory organizations
The United Nations Committee o f Experts on the Transport o f Dangerous 
Goods is continually developing recommendations for the safe transport of 
dangerous goods. The International Civil Aviation Organization (ICAO) has used 
these recommendations as the basis for developing regulations for the safe 
transportation o f dangerous goods by air. The regulations o f the International Air 
Transport Association (IATA) contain all the requirements o f the ICAO Technical 
Instructions for the Safe Transport o f Dangerous Goods. However, IATA has 
included additional requirements that are more restrictive than those o f ICAO. 
Member airlines o f the IATA have adopted the use o f the IATA 
regulations governing dangerous goods, and shippers must comply with these 
regulations in addition to any applicable regulations o f the state o f origin, transit, 
or destination.
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The shipment o f infectious agents or diagnostic specimens by air must comply 
with local, national and international regulations. International air transport 
regulations may be found in the IATA publication entitled, Dangerous Goods 
Regulations. This reference is published annually in January, and frequently the 
regulations change from year to year. A copy o f the IATA regulations in English, 
Spanish, French, or German may be obtained from one o f the regional offices 
listed below.
Orders from the Americas, Europe, Africa, and the M iddle East:
Customer Service Representative








Orders from Asia, Australasia, and the Pacific:
Customer Service Representative 
International Air Transport Association 
77 Robinson Rd.











2. Shipping regulations for infectious substances and clinical/ 
diagnostic specimens
In general, all packages that are being shipped by air via commercial and cargo 
carriers such as Federal Express and passenger aircraft are affected by the IATA 
regulations. These regulations are outlined below as an example o f acceptable 
packaging procedures for infectious materials. However, because they may not 
reflect current national or IATA requirements for packaging and labeling for
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infectious substances, anyone packaging isolates or infectious specimens should 
consult the appropriate national regulations and the current edition o f D a n g ero u s  
Goods R e g u la t io n s  before packing and shipping infectious substances by any 
means o f transport.
D efin ition  o f  in fectiou s substances
Infectious substances are defined as substances known to contain, or reason­
ably expected to contain, pathogens. Pathogens are microorganisms (including 
bacteria, viruses, rickettsia, parasites, fungi) or recombinant microorganisms 
(hybrid or mutant) that are known or reasonably expected to cause infectious 
disease in humans or animals.
C lassification  o f  clinical/diagnostic specim ens
• Specimens (human, animal, food, environmental, etc.) known or reasonably 
expected to contain pathogens are now to be classified as infectious sub­
stances. When these specimens are transported/shipped for any purpose, 
including initial or confirmatory testing for the presence o f pathogens, they 
are to be packaged and shipped as infectious substances (see below).
• Specimens that have a relatively low probability o f containing pathogens are 
to be classified as clinical/diagnostic specimens. When these specimens are 
transported/shipped for the purpose of routine screening tests or initial 
diagnosis for other than the presence o f pathogens, they are to be packaged 
and shipped as clinical/diagnostic specimens.
• Those specimens known not to contain pathogens are to be packaged and 
shipped as nonrestricted, i.e., packaging and shipping is not regulated. They 
are to be packaged in watertight primary containers and leakproof secondary 
containers.
Unless it has been specifically determined, i.e., by testing, that a clinical/ 
diagnostic specimen does not contain a pathogen(s), it is considered to fall within 
the categories either o f those specimens known or reasonably expected to contain 
pathogens or those specimens that have a relatively low probability o f containing 
pathogens.
G uidelines fo r packaging and labeling in fectiou s substances
Persons who ship infectious agents or diagnostic specimens must comply with 
all local and international regulations pertaining to the packaging and handling of  
these items. They must ensure that specimens arrive at their destination in good 
condition and that they present no hazard to persons or animals during shipment.
The inner packaging must include the following:
• An inner watertight primary container that is glass, metal, or plastic and has 
a leakproof seal. Petri plates should not be shipped.
• A  watertight, impact-resistant secondary container
• Absorbent material between the primary container and the secondary
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container. If multiple primary containers are placed in a single secondary 
packaging, they must be wrapped individually to ensure that contact 
between them is prevented. The absorbing material, such as cotton wool, 
must be sufficient to absorb the entire contents of all primary containers.
• An itemized list o f contents between the secondary packaging and the outer 
packaging
Multiple primary receptacles placed in a single secondary packaging must be 
wrapped individually, or for infectious substances transported in liquid nitrogen, 
separated and supported to ensure that contact between them is prevented. The 
absorbing material must be sufficient to absorb the entire contents of all primary 
receptacles.
The outer packaging must meet the following requirements:
• Be of sufficient strength to adequately protect and contain the contents
• Be at least 100 mm (4 inches) in its smallest overall external dimension
• Be durably and legibly marked on the outside with the address and tele­
phone number o f the consignee. A biohazard warning label must be affixed 
to the outside o f the outer container, and must bear the inscription, “Infec­
tious substance. In case o f damage or leakage immediately notify public 
health authority.” Packaging for infectious substances must be marked with 
United Nations specification markings denoting that the packaging has been 
tested and certified for shipping infectious substances.
Figure 13-1 illustrates these packaging recommendations.
G uidelines fo r  packag ing  an d  labeling  clinical/diagnostic specim ens n o t fo r  
m icrobiologic exam ination
Clinical specimens with a low probability o f containing an infectious agent 
that are not being transported for examination for the presence o f pathogens 
must be packaged as follows:
• Be “triple packaged” as described above for infectious agents
• Be in packaging that will not leak after a 4-foot drop test
• Have a “Clinical Specimens” label affixed to the outside o f the outer 
container
• If being shipped by air, bear the following statement, “Contents not re­
stricted, packed in compliance with IATA packing instruction 650.”
Figure 13-2 illustrates these packaging recommendations.
Reference
International Air Transport Association. 1999. Annual publication. Dangerous 
goods regulations. Montreal, Quebec, Canada: IATA Publications Office.
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Diagnostic Supplies Needed for 1 Year for 
Laboratory Confirmation of Outbreaks and for 
Laboratory-Based Surveillance for Vibrio cholerae 
O1/O139 Antimicrobial Susceptibility
Assumptions:
• Supply each district with materials to collect and transport 50 specimens
• Supply each regional laboratory with materials to process 100 specimens
• Supply each national reference laboratory with materials to confirm 500 isolates
District Level
Supplies needed fo r  each d istrict
50 cotton swabs
50 bottles or tubes o f Cary-Blair (or other) transport medium 
Transport for specimens to regional laboratory
Regional Level
Supplies needed fo r  each regional laboratory
100 sterile cotton or polyester swabs
500 g Cary-Blair medium
500 g TCBS medium
25 g sodium desoxycholate
Glass slides for serologic testing and string test
5 g A^MLAfeetramethyl-D-phenylenediamine dihydrochloride (oxidase reagent) 
Filter paper for oxidase test
Sterile wooden sticks or platinum inoculating loops for oxidase test 
500 g nonselective agar* (e.g., tryptone soy agar, heart infusion agar)
4 x 2 ml polyvalent V cholerae O1 diagnostic antiserum 
500 g Bacto-peptone medium 
500 g NaCl 
NaOH
pH paper or pH meter 
500 petri dishes (9 cm)
1000 test tubes (e.g., 13 x 100 mm or 16 x 125 mm)
Transport for specimens to reference laboratory
Materials and postage for production and dissemination o f reports
*Do not use nutrient agar because some formulations have no added salt and do 
not allow optimal growth o f V. cholerae.
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Supplies needed by  each na tiona l reference laboratory fo r  confirm ation
5 x 100 sterile cotton or polyester swabs
5 x 500 g Cary-Blair medium
5 x 500 g TCBS medium
5 x 25 g sodium desoxycholate
Glass slides for serologic testing and string test
5 x 5 g A^ALrALftetramethyl-D-phenylenediamine dihydrochloride (oxidase reagent) 
Filter paper
Sterile wooden sticks or platinum inoculating loops 
5 x 500 g nonselective agar* (e.g., tryptone soy agar, heart infusion agar)
20 x 2 ml polyvalent V. cholerae O1 diagnostic antiserum
5 x 2 ml V. cholerae O139 diagnostic antiserum
5 x 2 ml V. cholerae O1 serotype Ogawa diagnostic antiserum
5 x 2 ml V. cholerae O1 serotype Inaba diagnostic antiserum
5 x 500 g Bacto-peptone medium
5 x 500 g NaCl
NaOH
pH paper or pH meter 
5 x 500 petri dishes (9 cm)
5 x 1000 test tubes (e.g., 13 x 100 mm or 16 x 125 mm)
A ntim icrob ial suscep tib ility test supplies (d isk d iffu sio n  m ethod)
5 x 500 g Mueller-Hinton agar 
200 disks o f the following antibiotics
• Trimethoprim-sulfamethoxazole
• Chloramphenicol
• Furazolidone (if furazolidone is being considered for use in cholera treatment)
• Tetracycline
Control strain Escherichia coli ATCC 25922 
0.5 McFarland turbidity standard 
Sterile cotton swabs 
Sterile saline
Forceps and 95% alcohol for flaming 
Zone size criteria chart
Materials and postage for production and dissemination o f reports
*Do not use nutrient agar because some formulations have no added salt and do 




Supplies Needed for Laboratory Identification of 
Shigella dysenteriae 1 During an Outbreak
Assumptions:
• Supply each district with materials to collect and transport 50 specimens
• Supply each regional laboratory with materials to process 100 specimens
• Supply each national reference laboratory with materials to confirm 500 
isolates
District Level (Materials to collect and transport 50 specimens)
Supplies needed fo r  each d istrict 
100 cotton swabs
50 bottles or tubes o f Cary-Blair or other transport medium 
Transport for specimens to regional laboratory
Regional Level (Materials to process 100 specimens)
Supplies needed fo r  each regional laboratory
200 sterile cotton or polyester swabs
100 bottles or tubes o f Cary-Blair (or other) transport medium
500 g XLD medium
500 g MacConkey medium
500 g Kligler iron agar
500 g motility agar
500 g nonselective agar (e.g., tryptone soy agar, heart infusion agar) 
Diagnostic antisera:
4 x 2 ml monovalent S. dysenteriae serotype 1 (not Group A polyvalent)
2 x 2 ml polyvalent S. flexneri (Group B)
2 ml polyvalent S. sonnei (Group D)
Glass slides for serologic testing 
500 disposable petri dishes (9 cm)
1000 disposable test tubes (e.g., 13 x 100 mm or 16 x 125 mm)
Transport for specimens to reference laboratory
Materials and postage for production and dissemination o f reports
95
Annex B
Supplies needed by each na tiona l reference laboratory fo r  confirm ation
500 sterile cotton or polyester swabs
5 x 500 g Cary-Blair medium or other transport medium
5 x 500 g XLD medium
5 x 500 g MacConkey medium
3 x 500 g Kligler iron agar
3 x 500 g motility agar
3 x 500 g nonselective agar (e.g., tryptone soy agar, heart infusion agar) 
Diagnostic antisera:
20 x 2 ml monovalent S. dysenteriae serotype 1 (not Group A polyvalent) 
10 x 2 ml polyvalent S. flexneri (Group B)
5 x 2 ml polyvalent S. sonnei (Group D)
Glass slides for serologic testing 
5 x 500 disposable petri dishes (9 cm)
5 x 1000 disposable test tubes (e.g., 13 x 100 mm or 16 x 125 mm)
A ntim icrobial suscep tib ility test supplies fo r  100  Shigella isolates
2 x 500 g Mueller-Hinton Agar 
200 disposable petri dishes (9 cm)





Ciprofloxacin (1 cartridge only)
Control strain Escherichia coli ATCC 25922 
0.5 McFarland turbidity standard 
Sterile cotton swabs 
Sterile saline
Forceps and 95% alcohol for flaming 
Zone size criteria chart
Materials and postage for production and dissemination o f reports
National Reference Laboratory (Materials to confirm 500 isolates)
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Guidelines for Establishing a Public Health 
Laboratory Network for Cholera Control
Purpose
• To establish a routine system for confirming the presence of Vibrio cholerae O1
and O139.
• To monitor the antimicrobial susceptibility patterns o f V. cholerae O1 isolates
from throughout the country.
• To provide feedback to guide development o f appropriate antimicrobial
treatment policies for cholera.
Overview
When outbreaks of a cholera-like illness occur, there is a need for accurate data 
to confirm the presence o f V. cholerae O1. In addition, data about the antimicro­
bial susceptibility patterns o f V. cholerae O1 isolates from throughout the country 
are needed to develop an effective antimicrobial treatment policy. Following is an 
outline o f a system involving regional and reference laboratories to carry out these 
activities. Laboratories at different levels have corresponding degrees o f respon­
sibility for collection and transport o f specimens, identification and confirmation 
o f isolates, and feedback o f the results to the appropriate levels. The roles and 
responsibilities o f each level are outlined below, along with the basic supplies 
needed to carry out these activities. A full listing o f the supplies needed for a 
1-year period can be found in Annex A.
A. Surveillance
The laboratory-based surveillance will consist o f two parts:
• Initial confirmation o f the outbreak
• Ongoing surveillance for antimicrobial susceptibility o f the V. cholerae 
isolates.
1. Initial confirmation of the outbreak
In areas currently not experiencing a cholera outbreak, cholera should be 
suspected if  a patient older than 5 years develops severe dehydration or dies from 
acute watery diarrhea, or if  there is a sudden increase in the daily number of 
patients with acute watery diarrhea. If such events are noted, 5 to 10 stool 
specimens should be sent to the regional laboratory for confirmation. Specific 
instructions for collecting and transporting stools can be found in the WHO 
“Guidelines for Cholera Control” and in Chapter 2 in this manual. A stool 
specimen data sheet to send with the specimens is found in Annex F.
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Once the outbreak is confirmed, it is not necessary to collect specimens from 
additional patients for diagnosis. The diagnosis for treatment purposes can be 
made on clinical criteria. Collecting and processing an excessive number o f stool 
specimens can quickly deplete scarce laboratory resources.
In areas where cholera is known to be present, confirmation o f additional 
outbreaks is not necessary.
2. Surveillance for antimicrobial susceptibility of Vibrio cholerae 
isolates
Every 3 months, the regional laboratories in areas that are affected by cholera 
should each send 10 to 20 V. cholerae isolates to the national reference laboratory 
for susceptibility testing. The affected districts in the region should each send 
sufficient specimens for the regional laboratory to achieve this number. The 
regional laboratory should send these isolates to the reference laboratory for 
confirmation. A representative sample o f isolates from each reference laboratory 
(a total of 10 to 20) should periodically be sent to an international reference 
laboratory for confirmation o f the antimicrobial susceptibility pattern and possibly 
for additional studies, such as subtyping by ribotyping, pulsed-field gel electro­
phoresis or other molecular studies. Arrangements can be made through WHO 
for sending these isolates to an international reference laboratory on a regular 
basis.
B. Roles of District, Regional, and Reference Laboratories
1. District level
When an outbreak begins in a district, it should be confirmed by collecting 5 to 
10 stool specimens and sending them to the regional laboratory for confirmation 
o f the presence o f V. cholerae. The basic materials needed at the district level to 
collect the stool specimens are as follows:
• Cary-Blair (or other) transport medium in tubes
• Sterile swabs
Each district should have sufficient supplies to send 50 stool specimens to the 
regional laboratory. In addition, the district will need to develop a rapid and 
reliable means o f sending the specimens to the regional laboratory.
2. Regional level
The regional laboratory receives the specimen from the district and performs 
the initial isolation o f V. cholerae. Each region should have sufficient supplies to 
identify at least 100 isolates o f V. cholerae O1 and to send the isolates to the 
national reference laboratory for additional testing. The basic materials needed at 
the regional level are as follows:
• Thiosulfate citrate bile salts sucrose agar (TCBS) medium
• Ingredients to prepare alkaline peptone water
• Polyvalent O1 V. cholerae diagnostic antisera
98
Annex C
• Heart infusion agar (HIA) or other nonselective medium
• Petri dishes
• Tubes for transport (HIA used as transport medium for isolates)
3. Reference level
The regional laboratory sends isolates to a national reference laboratory for 
confirmation and antimicrobial susceptibility testing. Each reference laboratory 
will need sufficient materials to confirm at least 500 isolates sent from the 
regional level throughout the year. The basic materials needed are as follows:
• TCBS medium
• Ingredients to prepare alkaline peptone water
• Polyvalent O1 and O139 group V cholerae diagnostic antiserum
• Monovalent Ogawa diagnostic antiserum
• Monovalent Inaba diagnostic antiserum
• HIA or other nonselective medium
• Petri dishes
• Tubes for transport and storage o f isolates (HIA medium used for this)
• Supplies for antimicrobial susceptibility testing (see Annex B)
4. Referral to international reference laboratories
As part o f the laboratory-based surveillance process, isolates should periodi­
cally be sent to an international reference laboratory for confirmation of the 
antimicrobial susceptibility patterns. This is especially important if  strains exhibit 
a new or unusual antimicrobial susceptibility pattern. Arrangements can be made 
through WHO for sending such specimens to an international reference laboratory 
and to provide for the rapid feedback o f the results.
5. Feedback of Results
R egiona l laboratory to district, confirm ation o f  outbreak
When the regional laboratory confirms the presence o f V. cholerae O1 in stool 
specimens received from the district, it should contact the district as quickly as 
possible to inform the health authorities that V. cholerae O1 has been identified 
from the district.
R eference laboratories to regional laboratories
The reference laboratory should regularly communicate the results o f the 
studies carried out on isolates submitted from the regional laboratory. The results 
should be sent to the regional laboratory and to the Ministry o f Health. This 
includes the results o f isolates sent both for confirmation of outbreaks and for the 
routine surveillance for V. cholerae carried out every 3 months. These results can 
serve as an internal quality control for the regional laboratories. In addition, 
every 3 months summaries o f the results from all national reference laboratories 
should be distributed to the regional laboratories and appropriate persons in the 
Ministry o f Health for further distribution to all relevant parties.
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The international reference laboratory should provide timely feedback of  
results to the national reference laboratory that is coordinating the shipping o f the 
specimens. These results will be shared with the other reference laboratories and 
will serve as an external quality control for identification o f V. cholerae O1 and 
O139 and for determining the antimicrobial susceptibility of the these strains.
6. Additional components for network
This system could be expanded to include other bacterial pathogens, such as 
those causing dysentery. For instance, periodic surveillance o f isolates from 
patients presenting with bloody diarrhea could be done to determine the 
prevalence o f various organisms causing dysentery and their antimicrobial 
susceptibility patterns.
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Designing a Survey to Examine Antimicrobial 
Susceptibility of Organisms Causing Epidemic 
Diarrhea
Rationale
In many places where cholera and epidemic dysentery caused by Shigella 
dysenteriae serotype 1 occur, laboratory resources are scarce. In addition, the 
characteristics of the patient population may make it necessary to begin treatment 
and provide a full treatment course of an antimicrobial agent when the patient is 
first seen. The clinician cannot wait for test results. Often the test results and 
final antimicrobial susceptibility pattern take up to a week to determine.
One method of overcoming these shortcomings of laboratory testing of 
individual patients is to design and carry out a survey to determine the 
organisms causing epidemic diarrhea and their susceptibility patterns, use the 
information to choose an appropriate antimicrobial agent for treatment, then 
develop a treatment policy based on the syndrome (i.e., dysentery or watery 
diarrhea). This method will conserve resources and improve the case management 
of diarrhea.
Below is a basic outline o f how to carry out such a survey that can be adapted 
to local conditions. It is important for the laboratory and epidemiology depart­
ments to work together on studies o f this sort. Doing so fosters cooperation, 
shares the workload, and brings in additional expertise.
Methods
Location
Do the survey in locations that are representative o f the population. Include 
some urban and some rural health centers. The sites chosen should be easily 
accessible so that specimens can be quickly transported to the laboratory doing 
the survey. In addition, they should have sufficient patients with diarrhea to allow 
the health care worker to collect 10-20 specimens in a few days.
Tim ing
If possible, the survey should be done at the beginning o f the cholera or 
dysentery season when there are adequate numbers o f patients with diarrheal 
disease at clinics and when the information gained will help establish treatment 
policies and drug purchase for the coming year.
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Enough patients should be sampled to provide 40 to 50 isolates. Isolation rates 
range from 25% to 75%. Thus 100 patients is a reasonable target. Select enough 
sites with high enough patient flow to reach this target in 1 to 2 weeks.
L ogistics
Patients should be selected systematically, such as the first 5 patients in the 
morning; every third patient; or, in the case o f clinics with fewer patients, all 
patients presenting with bloody diarrhea or watery diarrhea that particular day.
The number of specimens collected should not overwhelm the laboratory.
If the survey is being carried out for dysentery, patients should, if  possible, 
currently have diarrhea with visible blood, been ill for fewer than 4 days, and not 
have received an antimicrobial agent before a stool specimen is collected. Patients 
should be given a cup to collect a stool sample. Examine the stool for blood. If 
blood is visible, take a swab of the stool and place it in refrigerated (4oC) transport 
medium (see Chapter 2 for instructions on transport of specimens). Dispose o f the 
stool cup so as to minimize the chance o f infecting other persons.
If the survey is being carried out for presumptive cholera, the patients should 
have acute watery diarrhea with illness for fewer than 4 days, and should not have 
received an antimicrobial agent before a stool specimen is collected. For cholera, 
it is preferable to focus on adults and children over age 2 (younger children have 
many other causes o f watery diarrhea that would reduce the yield of V cholerae O1).
Transport the specimens to the laboratory. Examine specimens and test the 
antimicrobial susceptibilities o f S. dysenteriae 1 and V. cholerae O1/O139 
isolated (see Annexes A  and B for necessary laboratory supplies).
What to Do with Results
Share the results with other health workers in the country, especially those 
involved in developing treatment policies or purchasing drugs. If the country has a 
health bulletin, use it to publish and disseminate the results. It is helpful to share 
the results with neighboring countries and with the country WHO office, or with 
the WHO Inter-country or Regional Office, so that they can be easily and quickly 
shared with the other countries in the area.
What to Do with the Isolates
Keep the isolates if  possible. Methods to do so are described in Chapter 10, 
“Storage o f Isolates.” Any unusual isolates or those with novel antimicrobial 
susceptibility patterns should be sent to a national or international reference 
laboratory for confirmation.
H o w  m a n y  p a tien ts
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S T O O L  S P E C I M E N  D A T A  S H E E T  -  E P I D E M I C  D I A R R H E A
C oun try__________________________________________________________ R e g io n_____________________
















Y e s /N o ' *
* Formed (F); Soft (S); W atery (W); Bloody-mucus (BM)
**Type of antibiotic, dose and number of days taken.
Collected by: Name & T it le ______________
Transm it results to: Name & T it le ______________















Shigella Escherichia coli Salmonella Salmonella ser. Typhi Vibrio cholerae
Kligler iron agar1’ K/A- A/AG- K/AG+ K/A(+) K/A-
Triple sugar iron agar" K/A- A/AG- K/AG+ K/A(+) A/A-
Lysine iron agar1 K/A- K/K- K/K+ K/K(+) K/K-
Lysine decarboxylation'-1* - + + + +
Motility“ - + + + +
Urea hydrolysis' - - - - -
Indole production' " + or - + - - +
Oxidase production' - - - - +
a For each of these organisms, variable reactions may occur.
b Reactions expressed as “slant/butt” ; K = alkaline; A = acid; G = gas produced; + = hydrogen sulfide (H2S) 
produced; (+) = weakly positive for H2S production; - = no H2S produced. 
c + = positive reaction; - = negative reaction. 
d For V cholerae, 1% salt (NaCl) added to biochemical formulation.
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Diagnostic Laboratory Supplies for Isolation and 
Presumptive Identification of Escherichia coli 
O157:H7 During an Outbreak (Sufficient for 100 
Specimens)
100 sterile cotton or polyester swabs 
500 g Cary-Blair or other transport medium 
500 g sorbitol MacConkey agar
500 g nonselective agar (e.g., tryptone soy agar, heart infusion agar) 
O157 latex agglutination kit for 100 tests 
200 petri dishes (9 cm)
200 test tubes (e.g., 13 x 100 mm or 16 x 125 mm)
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Suggested  Citation
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